Angiogenically effective unit dose of FGF-2 and method of use

ABSTRACT

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient&#39;s safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.09/771,302, filed Jan. 26, 2001 now abandoned, which is acontinuation-in-part of U.S. application Ser. No. 09/385,114, filed Aug.27, 1999, now U.S. Pat. No. 6,440,934, which claims the benefit of U.S.Provisional Application Ser. Nos. 60/104,103, filed Oct. 13, 1998, and60/104,102, filed Oct. 13, 1998; the contents of which are hereinincorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention is directed to a unit dose composition forinducing cardiac angiogenesis in a human comprising a therapeuticallyeffective amount FGF-2 or an angiogenically active fragment or muteinthereof. The present invention is also directed to a method foradministering a single unit dose composition to a human to inducecardiac angiogenesis while minimizing systemic risk to the patient. Thepresent invention is useful because the disclosed unit dose composition,and method for its administration, provide an alternative to angioplastyor surgical intervention for the treatment of coronary artery disease(CAD) and further provide an adjunct for reducing post myocardialinfarct (MI) injury in humans.

BACKGROUND OF THE INVENTION

The fibroblast growth factors (FGF) are a family of at least eighteenstructurally related polypeptides (named FGF-1 to FGF-18) that arecharacterized by a high degree of affinity for proteoglycans, such asheparin. The various FGF molecules range in size from 15–23 kD, andexhibit a broad range of biological activities in normal and malignantconditions including nerve cell adhesion and differentiation [Schubertet al., J. Cell Biol. 104:635–643 (1987)]; wound healing [U.S. Pat. No.5,439,818 (Fiddes)]; as mitogens toward many mesodermal and ectodermalcell types, as trophic factors, as differentiation inducing orinhibiting factors [Clements, et al., Oncogene 8:1311–1316 (1993)]; andas an angiogenic factor [Harada, J. Clin. Invest., 94:623–630 (1994)].Thus, the FGF family is a family of pluripotent growth factors thatstimulate to varying extents fibroblasts, smooth muscle cells,epithelial cells and neuronal cells.

When FGF is released by normal tissues, such as in fetal development orwound healing, it is subject to temporal and spatial controls. However,many of the members of the FGF family are also oncogenes. Thus, in theabsence of temporal and spatial controls, they have the potential tostimulate tumor growth while providing angiogenesis.

Coronary artery disease is a progressive condition in humans wherein oneor more coronary arteries gradually become occluded through the buildupof plaque (atherosclerosis). The coronary arteries of patients havingthis disease are often treated by balloon angioplasty or the insertionof stents to prop open the partially occluded arteries. Ultimately, manyof these patients are required to undergo coronary artery bypass surgeryat great expense and risk. It would be desirable to provide suchpatients with a medicament that would enhance coronary blood flow so asto reduce the need to undergo bypass surgery.

An even more critical situation arises in humans when a patient suffersa myocardial infarction, wherein one or more coronary arteries orarterioles becomes completely occluded, such as by a clot. There is animmediate need to regain circulation to the portion of the myocardiumserved by the occluded artery or arteriole. If the lost coronarycirculation is restored within hours of the onset of the infarction,much of the damage to the myocardium that is downstream from theocclusion can be prevented. The clot-dissolving drugs, such as tissueplasminogen activator (tPA), streptokinase, and urokinase, have beenproven to be useful in this instance. However, as an adjunct to the clotdissolving drugs, it would also be desirable to obtain collateralcirculation to the damaged or occluded myocardium by angiogenesis.

Accordingly, it is an object of the present invention to provide amedicament and a mode of administration that provides human patientswith cardiac angiogenesis during coronary artery disease and/or postacute myocardial infarction. More particularly, it is a further objectof the present invention to provide a therapeutic dose of an FGF and amode of administration to humans that provide the desired property ofcardiac angiogenesis, while minimizing adverse effects.

Many of the various FGF molecules have been isolated and administered tovarious animal models of myocardial ischemia with varying and oftentimes opposite results. According to Battler et al., “the canine modelof myocardial ischemia has been criticized because of the abundance ofnaturally occurring collateral circulation, as opposed to the porcinemodel, which ‘excels’ in its relative paucity of natural collateralcirculation and its resemblance to the human coronary circulation.”Battler et al., “Intracoronary Injection of Basic Fibroblast GrowthFactor Enhances Angiogenesis in Infarcted Swine Myocardium,” JACC,22(7): 2001–6 (December 1993) at page 2002, col. 1. However, Battler etal., who administered bovine bFGF (i.e., FGF-2) to pigs in a myocardialinfarct model, considered the varying results that are obtained from oneanimal species to another, and expressly discloses that the divergentresults “thus emphasiz[e] the caution that must be exercised inextrapolating results from different animal models.” Battler et al., atpage 2005, col. 1. Further, Battler points out that “the dosage and modeof administration of bFGF [i.e., bovine FGF-2] may have profoundimplications for the biologic effect achieved.” Battler, et al., at page2005, col. 1. Thus, it is a further object of this invention to discovera dosage and a mode of administration of a fibroblast growth factor thatwould provide for the safe and efficacious treatment of CAD and/or postMI injury in a human patient. More generally, it is an object of thepresent invention to provide a pharmaceutical composition and method forinducing angiogenesis in a human heart.

SUMMARY OF THE INVENTION

The Applicants have discovered that administering a single unit dose ofabout 0.2 μg/kg to about 48 μg/kg of rFGF-2 or an angiogenically activefragment or mutein thereof into one or more coronary vessels (IC) or aperipheral vein (IV) of a human patient in need of coronaryangiogenesis, unexpectedly provided the human patient with a rapid andtherapeutic coronary angiogenesis that resulted in an unexpectedly largeincrease (i.e., 96 and 100 seconds of increase in the mean change frombaseline for all groups at 2 and 6 months) in the treated patient'sexercise tolerance time (ETT) that persisted for an unexpectedly longduration (i.e., 6 months as of this writing). These changes shouldresult in a decreased need for standard revascularization procedures. Bythe term “coronary angiogenesis,” as used herein, is meant the formationof new blood vessels, ranging in size from capillaries to arterioleswhich act as collaterals in coronary circulation. By way of comparison,angioplasty is considered a therapeutic success if it provides anincrease in a patient's ETT of greater than 30 seconds compared to theplacebo.

Accordingly, in one aspect, the invention is directed to a unit dose ofrFGF-2 comprising a safe and therapeutically effective amount of rFGF-2or an angiogenically active fragment or mutein thereof. Typically, thesafe and therapeutically effective amount comprises about 0.2 μg/kg toabout 48 μg/kg of rFGF-2 or an angiogenically active fragment or muteinthereof, based upon ideal body weight. In other embodiments, the safeand therapeutically effective amount of the unit dose comprises 0.2μg/kg to 2.0 μg/kg, greater than 2.0 μg/kg to less than 24 μg/kg, or 24μg/kg to 48 μg/kg IC of rFGF-2 or an angiogenically active fragment ormutein thereof. In another embodiment, the safe and therapeuticallyeffective amount of the unit dose comprises 18 μg/kg to 36 μg/kg IV ofrFGF-2 or an angiogenically active fragment or mutein thereof. Expressedin absolute terms, the unit dose of the present invention comprises0.008 mg to 7.2 mg, more typically 0.3 mg to 3.5 mg, of FGF-2 or anangiogenically active fragment or mutein thereof. A suitable FGF-2 isthe rFGF-2 of SEQ ID NO: 2 or an angiogenically active fragment ormutein thereof.

In another aspect, the present invention is directed to a method oftreating a human patient for CAD or to induce coronary angiogenesistherein. The method comprises administering into one or more coronaryvessels or a peripheral vein of a human patient in need of treatment forcoronary artery disease (or in need of angiogenesis) a safe andtherapeutically effective amount of a recombinant FGF-2 (rFGF-2) or anangiogenically active fragment or mutein thereof. Typically, a portionof the safe and therapeutically effective amount is administered to eachof 2 coronary vessels. The safe and therapeutically effective amountcomprises about 0.2 μg/kg to about 48 μg/kg, of rFGF-2 or anangiogenically active fragment or mutein thereof in a pharmaceuticallyacceptable carrier. In other embodiments, the safe and therapeuticallyeffective amount comprises 0.2 μg/kg to 2 μg/kg, >2 μg/kg to <24 μg/kg,or 24 μg/kg to 48 μg/kg of rFGF-2 an angiogenically active fragment ormutein thereof in a pharmaceutically acceptable carrier. In absoluteterms, the amount of rFGF-2 or angiogenically active fragment or muteinthereof that is used in the above method comprises 0.008 mg to 7.2 mg,more typically 0.3 mg to 3.5 mg, of rFGF-2 or an angiogenically activefragment or mutein thereof.

Because FGF-2 is a glycosoaminoglycan (e.g., heparin) binding proteinand the presence of a glycosoaminoglycan optimizes activity and AUC (seeFIGS. 3 and 4), the IC dosages of RFGF-2 of the present inventiontypically are administered from 0–30 minutes prior to the administrationof a glycosoaminoglycan, such as a heparin. The heparin is administeredIC or IV, typically IV. Optionally, the heparin is combined with theunit dose composition.

Because rFGF-2 releases nitric oxide, a potent vasodilator, aggressivefluid management prior to (proactively) and during the infusion iscritical to patient's safety. Administration of IV fluids (e.g.,500–1000 mL of normal saline) to establish an estimated wedge pressureof 12 mm Hg prior to infusion and administration of boluses of IV fluids(e.g., 200 mL normal saline) for decreases of systolic blood pressure(e.g., <90 mm Hg) associated with infusion optimized the safety ofadministration of rFGF-2 by IC or IV infusion to human patients.

Because EDTA is a potent chelator of calcium which is required fornormal myocardial contraction and cardiac conduction, minimizing theconcentration of EDTA is critical to patient's safety. A concentrationof EDTA less than 100 μg/ml in the unit dose composition optimized thesafety of administration of rFGF-2 by IC or IV infusion to humanpatients.

Because a sudden bolus of rFGF-2 is associated with profound hypotensionin animals, the rate of infusion is critical to patient's safety.Administration at 0.5 to 2 mL per minute, typically 1 mL per minute,optimized the safety of administration of rFGF-2 by IC or IV infusion tohuman patients.

The unexpected magnitude and duration of the therapeutic benefit thatwas provided to human patients in need of coronary angiogenesis by theunit dose composition and method of administration was seen as early as2 weeks after the single unit dose was administered, and persisted for 6months after the single unit dose was administered IC or IV, asdetermined by measuring art-recognized clinical endpoints such as ETT,the “Seattle Angina Questionnaire” (SAQ) and MRI of the target areas ofthe heart. See, for example, Spertus et al. (1995) JACC 25:333–341. Inparticular, when the ETT of 58 human CAD patients was assessed bytreadmill at baseline, and at 1 month, 2 months, and 6 months afteradministration of a single unit dose of rFGF-2 by IC or IV routes,clinical benefit was observed in some patients in all dosage groups. SeeTable 1. Increases in exercise capacity appear between 1 and 2 months.The mean ETT increased to greater than 60 seconds at 2 and 6 months withgreater benefit being seen in the higher dose group (24–48 μg/kg) thanin the mid (6–12 μg/kg) or low (0.33–2.0 μg/kg) dose groups. (See Table1.) Particularly unexpected and unpredicted by animal models, were themean increases in ETT in human patients of 93.4 and 87.5 seconds thatwere observed at 2 and 6 months, respectively, post-dosing for thosepatients administered a unit dose of rFGF-2 by IV. Even assuming aplacebo effect, the mean change from baseline for the ETT seconds stillallowed an unexpectedly favorable comparison of results withangioplasty.

When the quality of life of 48 human CAD patients were assessed by avalidated, disease specific questionnaire, the Seattle AnginaQuestionnaire (SAQ), at baseline (i.e., prior to dosing), and at 2 and 6months after a single receiving a single unit dose of rFGF-2 of thepresent invention by IC or IV routes, the mean change from baseline forthe 5 scales measured by the SAQ increased in a clinically significantmanner for all dosage ranges whether administered IC or IV. (Tables2–6). In particular, the five scales assessed by the SAQ are exertionalcapacity, angina stability, angina frequency, treatment satisfaction,and disease perception. Relative to the baseline, the mean score forexertional capacity increased by 10.9 to 20.2 at 2 months; and by 16.5to 24.1 at 6 months. For angina stability, the mean score increased by32.1 to 46.2 at 2 months; and by 16.7 to 23.2 at 6 months. For anginafrequency, the mean score increased by 20.0 to 32.9 at 2 months; and by11.4 to 36.7 at 6 months. For treatment satisfaction, the mean scoreincreased by 8.5 to 19.8 at 2 months; and by 6.3 to 19.8 at 6 months.For disease perception, the mean score increased by 20.2 to 27.8 at 2months; and by 23.8 to 34.0 at 6 months. Generally, a change of 8 pointson any scale is considered clinically significant. Thus, the observedchanges of 8.5–46.2 are clinically significant for each of the fivescales that were assessed. Even assuming a placebo effect whereby a meanchange from baseline of 14 points is considered clinically significant,the results still provide for an unexpectedly superior effect at almostall scales that were assessed.

As part of this study, MRI was also performed on 33 human patientsdiagnosed with CAD to assess the effect of administering a single unitdose of rFGF-2 on their cardiac ejection fraction, regional myocardialfunction and perfusion (delayed arrival zone). Specifically, thepatients were administered a single unit dose of 0.33 μg/kg to 48 μg/kgIC or 18 μg/kg to 36 μg/kg IV of rFGF-2 of SEQ ID NO: 2. When the 33human CAD patients were assessed by resting cardiac magnetic resonanceimaging (MRI) at baseline (i.e., prior to treatment), and 1, 2 and 6months after treatment with a single unit dose of rFGF-2 of theinvention by IC or IV routes, the patients exhibited a highlystatistically significant response to the method of treatment asobjectively measured by increased target wall thickening, target wallmotion, and target area collateral extent, and by decreased target areadelayed arrival extent. By way of summary, at 1, 2 and 6 months, thetarget wall thickening increased relative to baseline at 4.4%, 6.3% and7.7%, respectively; the target wall motion increased relative tobaseline at 2.7%, 4.4% and 6.4%, respectively; the target areacollateral extent increased relative to baseline at 8.3%, 10.9% and11.2%, respectively; and the target area delayed arrival extentdecreased relative to baseline at −10.0%, −8.3% and −10.0%,respectively.

The above data demonstrates the clinical efficacy in humans of thepresent unit dose composition of rFGF-2 or an angiogenically activefragment thereof when administered IC or IV in accordance with thepresent invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is a plot of the mean rFGF-2 plasma concentration versus timeprofiles for eight different doses of rFGF-2 (SEQ ID NO: 2) administeredby IC infusion in humans over a 20 minute period. The eight doses ofrFGF-2 presented in FIG. 1A are 0.33, 0.65, 2, 6, 12, 24, 36, and 48μg/kg of lean body mass (LBM).

FIG. 1B is a plot of the mean FGF-2 plasma concentration versus timeprofiles for 2 different doses of rFGF-2 (SEQ ID NO: 2) administered byIV infusion in humans over a 20 minute period. The 2 IV doses of rFGF-2in FIG. 1B are 18 and 36 μg/kg. The mean concentration-time profilefollowing IC administration of 36 μg/kg rFGF-2 is included forcomparison.

FIG. 2 is a plot of mean FGF-2 area under the curve (AUC) in pg*min/mlcorresponding to FIGS. 1A and 1B. This plot shows the dose linearity ofsystemic rFGF-2 exposure following IC or IV infusion. The systemicexposure for the IC route is similar to that observed following IVadministration.

FIG. 3 is a plot of individual human patient FGF-2 plasma clearance (CL)values as a function of the time of heparin administration in “minutesprior to rFGF-2 infusion” and shows the influence of timing of heparinadministration on rFGF-2 plasma clearance (CL).

FIG. 4 is a plot individual human patient FGF-2 dose normalized areaunder curves (AUCs) as a function of the time of heparin administrationin “minutes prior to rFGF-2 infusion” and shows the influence of timingof heparin administration on FGF-2 AUC.

FIG. 5 summarizes the analysis plan for the Phase II Clinical Trial.

FIG. 6 summarizes patient characteristics for the patient population inthe Phase II Clinical Trial.

FIG. 7 shows patient disposition over the course of the Phase IIClinical Trail.

FIG. 8 shows the safety variables for the patient population for thePhase II Clinical Trial.

FIG. 9 depicts change in exercise time for the placebo, and 3 FGF-2treatment groups.

FIG. 10 shows the change in angina frequency score for patients inplacebo and the three treatment groups.

FIG. 11 shows the change in other domains of the Seattle AnginaQuestionnaire for patients in placebo and the three treatment groups.

FIG. 12 shows change in Short Form-36 physical component summary score.

FIG. 13 shows change in ETT and angina frequency score stratified bybaseline CCS Class 3 or 4.

FIG. 14 shows the change in ETT and angina frequency score stratified bybaseline AFS less than or equal to 40.

DETAILED DESCRIPTION OF THE INVENTION

The Applicants have discovered that a single dose of rFGF-2 or anangiogenically active fragment or mutein thereof, when administered in asafe and therapeutically effective amount into one or more coronaryvessels or into a peripheral vein of a human patient diagnosed with CADprovides the patient with a safe and therapeutically efficacioustreatment for the patient's coronary artery disease that lasts at least4 to 6 months, more typically at least 2 months, before a furthertreatment is needed. This duration of the effect and the magnitude ofthe improvements in ETT, SAQ and MRI were unexpected for a single unitdose of medicament.

By the phrase “therapeutically effective amount” or “safe andtherapeutically effective amount” as used herein in relation to rFGF-2is meant an amount of rFGF-2 or an angiogenically active fragment ormutein thereof that when administered in accordance with this invention,is free from major complications that cannot be medically managed, andthat provides for objective cardiac improvement in patients havingsymptoms of CAD despite optimum medical management. Thus, acutehypotension that can be managed by administration of fluids, isconsidered “safe” for the purpose of this invention. Typically, the safeand therapeutically effective amount of rFGF-2 comprises about 0.2 μg/kgto about 48 μg/kg of rFGF-2 or an angiogenically active fragment ormutein thereof. A suitable FGF-2 for use in the present invention is therFGF-2 of SEQ ID NO: 2 or an angiogenically active fragment or muteinthereof.

Accordingly, the present invention has multiple aspects. In its firstaspect, the present invention is directed to a unit dose composition forinducing angiogenesis in a human patient, the unit dose comprising atherapeutically effective (i.e., an angiogenically effective) amount ofrFGF-2 or an angiogenically active fragment or mutein thereof, theamount comprising about 0.2 μg/kg to about 48 μg/kg of rFGF-2 or anangiogenically active fragment or mutein thereof.

By the term “unit dose composition” as used herein is meant acomposition that when administered to a human patient in accordance withthe method of the present invention provides a typical human patient inneed of angiogenesis with an angiogenic effect of significant efficacyso as not to require retreatment for at least 4–6 months, typically 6months. The unit dose composition of the present invention is typicallyprovided in combination with one or more pharmaceutically acceptableexcipients or carriers. In other embodiments of the unit dosecomposition, a safe and therapeutically effective amount comprises about0.2 μg/kg to about 2 μg/kg, about 2 μg/kg to about 24 μg/kg, or about 24μg/kg to about 48 μg/kg of rFGF-2 or an angiogenically active fragmentor mutein thereof.

It is convenient to define the unit dose composition of the presentinvention in more absolute terms that are not dependent upon the weightof the patient to be treated. When so defined, the unit dose compositioncomprises from 0.008 mg to 7.2 mg of rFGF-2 or an angiogenically activefragment or mutein thereof. In this embodiment, the unit dosecomposition contains a sufficient amount of FGF-2 to accommodate dosingany one of the majority of human CAD patients, ranging from the smallestpatient (e.g., 40 kg) at the lowest dosage (about 0.2 μg/kg) through thelarger patients (e.g., 150 kg) at the highest dosage (about 48 μg/kg).More typically, the unit dose comprises 0.3 mg to 3.5 mg of rFGF-2 or anangiogenically active fragment or mutein thereof. The unit dosecomposition is typically provided in solution or lyophilized formcontaining the above referenced amount of rFGF-2 and an effective amountof one or more pharmaceutically acceptable buffers, stabilizers and/orother excipients as later described herein.

The active agent in the above described unit dose composition is arecombinant FGF-2 or an angiogenically active fragment or muteinthereof. Methods for making recombinant FGF-2 are well-known in the art.The recombinant FGF-2 of SEQ ID NO: 2 is made as described in U.S. Pat.No. 5,155,214, entitled “Basic Fibroblast Growth Factor,” which issuedon Oct. 13, 1992, and which is expressly incorporated herein byreference in its entirety. Moreover, all other references cited herein,whether occurring before or after this sentence, are expresslyincorporated herein by reference in their entirety. As disclosed in the'214 patent, a DNA of SEQ ID NO: 1, which encodes a bFGF (hereinafter“FGF-2”) of SEQ ID NO: 2, is inserted into a cloning vector, such aspBR322, pMB9, Col E1, pCRI, RP4 or λ-phage, and the cloning vector isused to transform either a eukaryotic or prokaryotic cell, wherein thetransformed cell expresses the FGF-2. In one embodiment, the host cellis a yeast cell, such as Saccharomyces cerevisiae. The resultingfull-length FGF-2 that is expressed has 146 amino acids in accordancewith SEQ ID NO: 2. Although the FGF-2 of SEQ ID NO: 2 has fourcysteines, i.e., at residue positions 25, 69, 87 and 92, there are nointernal disulfide linkages. ['214 at col. 6, lines 59–61.] However, inthe event that cross-linking occurred under oxidative conditions, itwould likely occur between the residues at positions 25 and 69.

The FGF-2 of SEQ ID NO: 2, which has 146 amino acid residues, differsfrom naturally occurring human FGF-2 by only 2 amino acid residue. Inparticular, the amino acids at residue positions 112 and 128 of theFGF-2 of SEQ ID NO: 2 are Ser and Pro, respectively, whereas in humanFGF-2, they are Thr and Ser, respectively. In nature, bovine FGF-2, likethe corresponding human FGF-2 is initially synthesized in vivo as apolypeptide having 155 amino acid residues. Abraham et al. “Human BasicFibroblast Growth Factor: Nucleotide Sequence and Genomic Organization,”EMBO J., 5(10):2523–2528 (1986). When the FGF-2 of SEQ ID NO: 2 iscompared to the full length 155 residue bovine FGF-2 of Abraham, theFGF-2 of SEQ ID NO: 2 lacks the first nine amino acid residues, Met AlaAla Gly Ser Ile Thr Thr Leu (SEQ ID NO: 3), at the N-terminus of thecorresponding full length molecule. The recombinant FGF-2 employed inthe present compositions and method was purified to pharmaceuticalquality (98% or greater purity) using the techniques described in detailin U.S. Pat. No. 4,956,455, entitled “Bovine Fibroblast Growth Factor”which issued on Sep. 11, 1990 and which is incorporated herein byreference in its entirety. In particular, the first 2 steps employed inthe purification of the recombinant FGF-2 of Applicants' unit dosecomposition are “conventional ion-exchange and reverse phase HPLCpurification steps as described previously.” [U.S. Pat. No. 4,956,455,citing to Bolen et al., PNAS USA 81:5364–5368 (1984).] The third step,which the '455 patent refers to as the “key purification step” ['455 atcol. 7, lines 5–6], is heparin-SEPHAROSE® affinity chromatography,wherein the strong heparin binding affinity of the FGF-2 is utilized toachieve several thousand-fold purification when eluting at approximately1.4M and 1.95M NaCl ['455 at col. 9, lines 20–25]. Polypeptidehomogeneity was confirmed by reverse-phase high pressure liquidchromatography (RP-HPLC). Buffer exchange was achieved by SEPHADEX®G-25(M) gel filtration chromatography.

In addition to the 146 residue rFGF-2 of SEQ ID NO: 2, the active agentin the unit dose of the present invention also comprises an“angiogenically active fragment” of FGF-2. By the term “angiogenicallyactive fragment” of FGF-2 is meant a fragment of FGF-2 that has about80% of the 146 residues of SEQ ID NO: 2 and that retains at least 50%,preferably at least 80%, of the angiogenic activity of the FGF-2 of SEQID NO: 2.

To be angiogenically active, the FGF-2 fragment should have two cellbinding sites and at least one of the two heparin binding sites. The twoputative cell binding sites of the analogous human FGF-2 occur atresidue positions 36–39 and 77–81 thereof. See Yoshida, et al., “GenomicSequence of hst, a Transforming Gene Encoding a Protein Homologous toFibroblast Growth Factors and the int-2-Encoded Protein,” PNAS USA,84:7305–7309 (October 1987) at FIG. 3. The two putative heparin bindingsites of hFGF-2 occur at residue positions 18–22 and 107–111 thereof.See Yoshida (1987) at FIG. 3. Given the greater than 98% similaritybetween the amino acid sequences for naturally occurring human FGF-2(hFGF-2) and rFGF-2 (SEQ ID NO: 2), it is expected that the 2 cellbinding sites for rFGF-2 (SEQ ID NO: 2) are also at residue positions36–39 and 77–81 thereof, and that the 2 heparin binding sites are atresidue positions 18–22 and 107–111 thereof. Consistent with the above,it is well known in the art that N-terminal truncations of the FGF-2 ofSEQ ID NO: 2 do not eliminate its activity in cows. In particular, theart discloses several naturally occurring and biologically activefragments of the FGF-2 that have N-terminal truncations relative to theFGF-2 of SEQ ID NO: 2. An active and truncated bFGF-2 having residues12–146 of SEQ ID NO: 2 was found in bovine liver and another active andtruncated bFGF-2, having residues 16–146 of SEQ ID NO: 2 was found inthe bovine kidney, adrenal glands and testes. [See U.S. Pat. No.5,155,214 at col. 6, lines 41–46, citing to Ueno, et al., Biochem andBiophys Res. Comm., 138:580–588 (1986).] Likewise, other fragments ofthe bFGF-2 of SEQ ID NO: 2 that are known to have FGF activity are FGF-2(24–120)—OH and FGF-2 (30–110)—NH₂. [U.S. Pat. No. 5,155,214 at col. 6,lines 48–52.] These latter fragments retain both of the cell bindingportions of FGF-2 (SEQ ID NO: 2) and one of the heparin binding segments(residues 107–111). Accordingly, the angiogenically active fragments ofFGF-2 typically encompass those terminally truncated fragments of FGF-2that have at least residues that correspond to residues 30–110 of FGF-2of SEQ ID NO: 2; more typically, at least residues that correspond toresidues 18–146 of FGF-2 of SEQ ID NO: 2.

The unit dose of the present invention also comprises an “angiogenicallyactive . . . mutein” of the rFGF-2 of SEQ ID NO: 2. By the term“angiogenically active . . . mutein” as used herein, is meant anisolated and purified recombinant protein or polypeptide that has 65%sequence identity (homology) to any naturally occurring FGF-2, asdetermined by the Smith-Waterman homology search algorithm (Meth. Mol.Biol. 70:173–187 (1997)) as implemented in MSPRCH program (OxfordMolecular) using an affine gap search with the following searchparameters: gap open penalty of 12, and gap extension penalty of 1, andthat retains at least 50%, preferably at least 80%, of the angiogenicactivity of the naturally occurring FGF-2 with which it has said atleast 65% sequence identity. Preferably, the angiogenically activemutein has at least 75%, more preferably at least 85%, and mostpreferably, at least 90% sequence identity to the naturally occurringFGF-2. Other well-known and routinely used homology/identity scanningalgorithm programs include Pearson and Lipman, PNAS USA, 85:2444–2448(1988); Lipman and Pearson, Science, 222:1435 (1985); Devereaux et al.,Nuc. Acids Res., 12:387–395 (1984); or the BLASTP, BLASTN or BLASTXalgorithms of Altschul, et al., Mol. Biol., 215:403–410 (1990).Computerized programs using these algorithms are also available andinclude, but are not limited to: GAP, BESTFIT, BLAST, FASTA and TFASTA,which are commercially available from the Genetics Computing Group (GCG)package, Version 8, Madison Wis., USA; and CLUSTAL in the PC/Geneprogram by Intellegenetics, Mountain View Calif. Preferably, thepercentage of sequence identity is determined by using the defaultparameters determined by the program.

The phrase “sequence identity,” as used herein, is intended to refer tothe percentage of the same amino acids that are found similarlypositioned within the mutein sequence when a specified, contiguoussegment of the amino acid sequence of the mutein is aligned and comparedto the amino acid sequence of the naturally occurring FGF-2.

When considering the percentage of amino acid sequence identity in themutein, some amino acid residue positions may differ from the referenceprotein as a result of conservative amino acid substitutions, which donot affect the properties of the protein or protein function. In theseinstances, the percentage of sequence identity may be adjusted upwardsto account for the similarity in conservatively substituted amino acids.Such adjustments are well-known in the art. See, e.g., Myers and Miller,“Computer Applic. Bio. Sci., 4:11–17 (1988).

To prepare an “angiogenically active mutein” of an angiogenic agent ofthe present invention, one uses standard techniques for site directedmutagenesis, as known in the art and/or as taught in Gilman, et al.,Gene, 8:81 (1979) or Roberts, et al., Nature, 328:731 (1987). Using oneof the site directed mutagenesis techniques, one or more point mutationsare introduced into the cDNA sequence of SEQ ID NO: 1 to introduce oneor more amino acid substitutions or an internal deletion. Conservativeamino acid substitutions are those that preserve the general charge,hydrophobicity/hydrophilicity, and/or steric bulk of the amino acidbeing substituted. By way of example, substitutions between thefollowing groups are conservative: Gly/Ala, Val/Ile/Leu, Lys/Arg,Asn/Gln, Glu/Asp, Ser/Cys/Thr, and Phe/Trp/Tyr. Significant (up to 35%)variation from the sequence of the naturally occurring angiogenic FGF-2is permitted as long as the resulting protein or polypeptide retainsangiogenic activity within the limits specified above.

Cysteine-depleted muteins are muteins within the scope of the presentinvention. These muteins are constructed using site directed mutagenesisas described above, or according to the method described in U.S. Pat.No. 4,959,314 (“the '314 patent”), entitled “Cysteine-Depleted Muteinsof Biologically Active Proteins.” The '314 patent discloses how todetermine biological activity and the effect of the substitution.Cysteine substitution is particularly useful in proteins having 2 ormore cysteines that are not involved in disulfide formation. Suitablesubstitutions include the substitution of serine for one or both of thecysteines at residue positions 87 and 92, which are not involved indisulfide formation. Preferably, substitutions are introduced at theFGF-2 N-terminus, which is not associated with angiogenic activity.However, as discussed above, conservative substitutions are suitable forintroduction throughout the molecule.

The unit dose composition of the present invention comprises a safe andan angiogenically effective dose of rFGF-2 or an angiogenically activefragment or mutein thereof, and a pharmaceutically acceptable carrier.Typically, the safe and angiogenically effective dose of thepharmaceutical composition of the present invention is in a form and asize suitable for administration to a human patient and comprises (i)0.2 μg/kg to 48 μg/kg of rFGF-2 or an angiogenically active fragment ormutein thereof, (ii) and a pharmaceutically acceptable carrier. In otherembodiments, the safe and angiogenically effective dose comprises 0.2μg/kg to 2 μg/kg, >2 μg/kg to <24 μg/kg or 24 μg/kg to 48 μg/kg of FGF-2or an angiogenically active fragment or mutein thereof, and apharmaceutically acceptable carrier. Expressed in absolute terms for themajority of human CAD patients, the unit dose of the present inventioncomprises 0.008 mg to 7.2 mg, more typically 0.3 mg to 3.5 mg, of theFGF-2 or an angiogenically active fragment or mutein thereof.

The second recited component of the unit dose composition of the presentinvention is a “pharmaceutically acceptable carrier.” By the term“pharmaceutically acceptable carrier” as used herein is meant any of thecarriers or diluents that are well-known in the art for thestabilization and/or administration of a proteinaceous medicament thatdoes not itself induce the production of antibodies harmful to thepatient receiving the composition, and which may be administered withoutundue toxicity. The choice of the pharmaceutically acceptable carrierand its subsequent processing enables the unit dose composition of thepresent invention to be provided in either liquid or solid form.

When the unit dose composition is in liquid form, the pharmaceuticallyacceptable carrier comprises a stable carrier or diluent suitable forintravenous (“IV”) or intracoronary (“IC”) injection or infusion.Suitable carriers or diluents for injectable or infusible solutions arenontoxic to a human recipient at the dosages and concentrationsemployed, and include sterile water, sugar solutions, saline solutions,protein solutions or combinations thereof.

Typically, the pharmaceutically acceptable carrier includes a buffer andone or more stabilizers, reducing agents, anti-oxidants and/oranti-oxidant chelating agents. The use of buffers, stabilizers, reducingagents, anti-oxidants and chelating agents in the preparation of proteinbased compositions, particularly pharmaceutical compositions, iswell-known in the art. See, Wang et al., “Review of Excipients and pHsfor Parenteral Products Used in the United States,” J. Parent. DrugAssn., 34(6):452–462 (1980); Wang et al., “Parenteral Formulations ofProteins and Peptides: Stability and Stabilizers,” J. Parent. Sci. andTech., 42: S4–S26 (Supplement 1988); Lachman, et al., “Antioxidants andChelating Agents as Stabilizers in Liquid Dosage Forms-Part 1, ” Drugand Cosmetic Industry, 102(1): 36–38, 40 and 146–148 (1968); Akers, M.J., “Antioxidants in Pharmaceutical Products,” J. Parent. Sci. andTech., 36(5):222–228 (1988); and Methods in Enzymology, Vol. XXV,Colowick and Kaplan Eds., “Reduction of Disulfide Bonds in Proteins withDithiothreitol,” by Konigsberg, pages 185–188. Suitable buffers includeacetate, adipate, benzoate, citrate, lactate, maleate, phosphate,tartarate and the salts of various amino acids. See Wang (1980) at page455. Suitable stabilizers include carbohydrates such as threlose orglycerol. Suitable reducing agents, which maintain the reduction ofreduced cysteines, include dithiothreitol (DTT also known as Cleland'sreagent) or dithioerythritol at 0.01% to 0.1% wt/wt; acetylcysteine orcysteine at 0.1% to 0.5% (pH 2–3); and thioglycerol at 0.1% to 0.5% (pH3.5 to 7.0) and glutathione. See Akers (1988) at pages 225 to 226.Suitable antioxidants include sodium bisulfite, sodium sulfite, sodiummetabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, andascorbic acid. See Akers (1988) at pages 225. Suitable chelating agents,which chelate trace metals to prevent the trace metal catalyzedoxidation of reduced cysteines, include citrate, tartarate,ethylenediaminetetraacetic acid (EDTA) in its disodium, tetrasodium, andcalcium disodium salts, and diethylenetriamine pentaacetic acid (DTPA).See e.g., Wang (1980) at pages 457–458 and 460–461, and Akers (1988) atpages 224–227. Suitable sugars include glycerol, trehalose, glucose,galactose and mannitol, sorbitol. A suitable protein is human serumalbumin.

In liquid form, a typical unit dose composition of the present inventioncomprises from about 0.001 mg to 8 mg, more typically 0.03 to 5 mgrFGF-2 or an angiogenically active fragment or mutein thereof, dissolveda pharmaceutically acceptable carrier. A suitable pharmaceuticallyacceptable carrier comprises 10 mM thioglycerol, 135 mM NaCl, 10 mMsodium citrate, and 1 mM EDTA, pH 5. A suitable diluent or flushingagent for the above-described unit dose composition is any of theabove-described carriers. Typically, the diluent is the carriersolution. rFGF-2 or an angiogenically active fragment or mutein thereofis unstable for long periods of time in liquid form. To maximizestability and shelf life of the liquid form, the unit dose compositionshould be stored frozen at −60° C. When thawed, the solution is stablefor 6 months at refrigerated conditions. A typical unit dose wouldcomprise about 1–40 ml, more typically 10–40 ml, of the above-describedcomposition having 0.008–7.2 mg of rFGF-2 or an angiogenically activefragment or mutein dissolved therein. A suitable rFGF-2 for use in theunit dose is the rFGF-2 of SEQ ID NO: 2 or an angiogenically activefragment or mutein thereof.

In another embodiment, the unit dose composition is provided inlyophilized (freeze-dried) form. In this form, the unit dose of rFGF-2is capable of being stored at refrigerated temperatures forsubstantially longer than 6 months without loss of therapeuticeffectiveness. Lyophilization is accomplished by the rapid freeze drying(i.e., removing water) under reduced pressure of a plurality of vials,each containing the above described liquid form of the unit dose of therFGF-2 of the present invention therein. Lyophilizers, which perform theabove described lyophilization, are commercially available and readilyoperable by those skilled in the art. The resulting lyophilized unitdose composition, in lyophilized cake form, is formulated to containwithin the resulting lyophilized cake one or more of the buffers,stabilizers, anti-oxidants, reducing agents, salts and/or sugarsdescribed above for the corresponding liquid formulation. A lyophilizedunit dose composition containing all such other components need only bereconstituted to a known volume or concentration with sterile aqueousdiluent such as sterile water, a sterile sugar solution, or a sterilesaline solution. Alternatively, it could be reconstituted with a sterilebuffer solution as described above, but lacking a chelating agent, suchas EDTA. As a lyophilized cake, the unit dose composition is stable from6 months to 2 years at refrigerated temperatures. Thus, storage of theunit dose composition in lyophilized form is readily accommodated usingconventional refrigeration equipment.

Because the unit dose composition of the present invention isadministered via a cardiac catheter or other injection device, which hasdead space, it is convenient to formulate the vial containing the unitdose composition so that it contains about 10–50% more of the rFGF-2 orangiogenically active fragment or mutein thereof than is to beadministered to the patient. For example, when the unit dose of therFGF-2 to be administered is 7.2 mg, the vial is optionally formulatedto contain up to 50% extra (e.g., a total of about 10.8 mg) of rFGF-2 orangiogenically active fragment or mutein thereof. The extra solution issuitable for filling the dead space in the delivery equipment. In analternative embodiment that does not allow for dead space, thepharmaceutical composition is loaded in the cardiac catheter in front ofa pharmaceutically acceptable buffer, diluent or carrier, which is thenused to deliver the appropriate amount of the one or more dosages to theone or more sites in the myocardium that are in need of angiogenesis.

As discussed above, the pharmaceutically acceptable carrier for theabove described unit dose composition comprises a buffer and one or morestabilizers, reducing agents, anti-oxidants and/or anti-oxidantchelating agents. It is also within the scope of the present inventionthat the unit dose composition contain an amount of a glycosoaminoglycan(also known as a “proteoglycan” or a “mucopolysaccharide”), such asheparin, that is effective to bind to the FGF-2 and to the endothelialcell receptors so as to enhance the angiogenic effectiveness of theFGF-2 or angiogenically active fragment or mutein thereof. The amount ofheparin that is administered is about 10–80 U per kg of patient weight(U/kg), typically about 40 U/kg. Expressed in absolute terms, the totalamount of heparin administered to any one patient does not exceed 5,000U. Thus, upon reconstitution, the unit dose composition of the presentinvention would not only contain an angiogenically effective amount ofrFGF-2 or an angiogenically active fragment or mutein thereof, it wouldalso contain from about 10–80 U/kg of heparin, typically about 40 U/kg.The typical volume of diluent is from about 1 to 40 ml. While largervolumes of diluent could be used, such larger volumes would typicallyresult in longer administration times. Depending upon the weight of thepatient in kg, a single dose comprising from 0.2 μg/kg to 48 μg/kg ofthe rFGF-2 or an angiogenically active fragment or mutein thereof iswithdrawn from the vial as reconstituted product for administration tothe patient. Thus, an average 70 kg man that is being dosed at 24 μg/kgwould have a sufficient volume of the reconstituted product withdrawnfrom the vial to receive an IC infusion of (70 kg×30 μg/kg) 2100 μg(i.e., 2.1 mg).

In its second aspect, the present invention is directed to a method fortreating a human patient for CAD or MI, using the above described unitdose composition. In particular, in one embodiment, the presentinvention is directed to a method for treating a human patient forcoronary artery disease, comprising administering a safe andtherapeutically effective amount of a recombinant FGF-2 or anangiogenically active fragment or mutein thereof to one or more,typically 2, patent coronary vessels or a peripheral vein of a humanpatient in need of treatment for coronary artery disease. The humanpatient in need of treatment for coronary artery disease is typically ahuman patient with coronary artery disease who remains symptomatic withangina despite optional medical management. A preferred coronary vesselis a coronary artery, although grafted saphenous veins and graftedinternal mammary arteries, as provided by coronary angioplasty, are alsosuitable. Suitable peripheral veins for administering the unit dosecomposition include those peripheral veins found throughout the humanbody that are routinely used by treating physicians and nurses foradministration of fluids and medicaments. Examples of such veins includethe cephalic, the median cubital, and the basilic of the arm.

When administered as an intracoronary (IC) infusion, the unit dose ofrFGF-2 or angiogenic fragment or mutein thereof is typicallyadministered within an hour, more typically over a period of about 20minutes into one or more (typically, 2) patent coronary vessels. Whenadministered over a twenty minute period, the unit dose composition istypically administered at a rate of 0.5 to 2.0 ml/minute, more typicallyat about 1 ml/minute. The coronary vessels can be native vessels orgrafts, so long as they are not occluded. The volume of the unit dose ofrFGF-2 or angiogenic fragment or mutein thereof is typically 10–40 ml;more typically 20 ml. The length of time for infusion of the unit doseis not critical and can be shortened or lengthened depending on the rateand volume of infusion

When administered as an intravenous (IV) infusion, the unit dose ofrFGF-2 or angiogenic fragment or mutein thereof is administeredtypically within an hour, more typically over a 20 minute period, into aperipheral vein using a conventional IV setup. When administered over atwenty minute period, the unit dose composition is typicallyadministered at a rate of 1 ml/minute.

In the phase I clinical trial of the above described method for treatingCAD, a single unit dose composition was administered IC or IV to humanpatients having CAD who remained symptomatic with angina despiteoptional medical management. Because the method of the present inventioninduces angiogenesis, the method of the present invention providestreatment of the underlying condition in CAD or MI and not merelytransitory relief from the symptoms, such as provided by nitrates.Typically, the safe and therapeutically effective amount of the methodof the present invention comprises 0.2 μg/kg to 48 μg/kg of rFGF-2 or anangiogenically active fragment or mutein thereof in a pharmaceuticallyacceptable carrier. In other embodiments, the safe and therapeuticallyeffective amount comprises 0.2 μg/kg to 2 μg/kg, >2 μg/kg to <24 μg/kg,or 24 μg/kg to 48 μg/kg of rFGF-2 or an angiogenically active fragmentor mutein thereof in a pharmaceutically acceptable carrier. In absoluteterms, the safe and therapeutically effective amount is about 0.008 mgto about 7.2 mg of rFGF-2 or an angiogenically active fragment or muteinthereof; more typically, 0.3 mg to 3.5 mg of rFGF-2 or an angiogenicallyactive fragment or mutein thereof. A suitable rFGF-2 is the rFGF-2 ofSEQ ID NO: 2 or an angiogenically active fragment or mutein thereof.

In another aspect, the present invention is also directed to a methodfor inducing angiogenesis in a heart of a human patient comprising,administering a single unit dose composition of a recombinant FGF-2 oran angiogenically active fragment or mutein thereof to one or morecoronary vessels or to a peripheral vein in a human patient in need ofcoronary angiogenesis, said unit dose composition comprising from about0.008 mg to 7.2 mg of recombinant rFGF-2 or an angiogenically activefragment or mutein thereof in a pharmaceutically acceptable carrier.More typically, the unit dose composition comprises about 0.3–3.5 mgrFGF-2 or an angiogenically active fragment or mutein thereof in apharmaceutically acceptable carrier. As described above, a single unitdose composition containing a therapeutically effective amount of anrFGF-2 or an angiogenically fragment or mutein thereof is administeredto at least one coronary vessel of a human patient in need ofangiogenesis, using standard cardiac catheterization techniques alreadyknown and used in the art for the intracoronary administration ofmedicaments, e.g., thrombolytics, streptokinase, or radio-opaque dyes ormagnetic particles used to visualize the coronary arteries. By way ofexample, a coronary catheter is inserted into an artery (e.g., femoralor subclavian) of the patient in need of treatment and the catheter ispushed forward, with visualization, until it is positioned in theappropriate coronary vessel of the patient to be treated. Using standardprecautions for maintaining a clear line, the pharmaceutical compositionin solution form is administered by infusing the unit dose substantiallycontinuously over a period of 10 to 30 minutes. Although thepharmaceutical composition of the invention could be administered over alonger period of time, the Applicants perceive no benefit and apotentially increased risk of thrombosis in doing so. Typically, aportion (e.g., one half) of the unit dose is administered in a firstcoronary vessel. Then, the catheter is repositioned into a secondsecondary coronary vessel and the remainder of the unit dose isadministered with flushing of the catheter. Using the above-describedrepositioning procedure, portions of the unit dose may be administeredto a plurality of coronary vessels until the entire unit dose has beenadministered. After administration, the catheter is withdrawn usingconventional art known protocols. In the phase I clinical trialsdescribed herein, therapeutic benefit was reported by patients as earlyas 2 weeks following the IC rFGF-2 administration of a single unit dose.Clinically significant improvement was demonstrable by objectivecriterion (ETT and/or SAQ) as early as 30 days following IC or IVadministration of a single unit dose of the present invention, and wasmaintained for 2 months following dosing. In certain patients withprogressive CAD disease, it may be necessary or appropriate toadminister additional unit doses of rFGF-2 at 2 or 12 month intervalsafter the initial unit dose, to overcome the progression of the CADduring that interim period. In some patients with very progressive CAD,unit doses of the present invention would be readministered at 4 monthintervals. In any instance, the treating physician would be able todetermine the time, if any, for readministration based upon routineassessment of the clinical symptoms of the patient.

One of the benefits of the method of the present invention is cardiacangiogenesis. Accordingly, in another aspect, the present invention isdirected to a method for inducing angiogenesis in a heart of a humanpatient, comprising administering into one or more coronary vessels (IC)or into a peripheral vein (IV) of a human patient in need of coronaryangiogenesis, a single unit dose composition comprising anangiogenically effective amount of rFGF-2 or an angiogenically activefragment or mutein thereof in a pharmaceutically acceptable carrier. Inthe above method, the angiogenically effective amount comprises about0.2 μg/kg to about 48 μg/kg (or in absolute terms about 0.008 mg toabout 7.2 mg) of a recombinant FGF-2 or an angiogenically activefragment or mutein thereof. More typically, the angiogenically effectiveamount comprises about 0.3 mg to 3.5 mg of a recombinant FGF-2 or anangiogenically active fragment or mutein thereof. A suitable rFGF-2 foruse in the above-identified method is the rFGF-2 of SEQ ID NO: 2 or anangiogenically active fragment thereof. In one embodiment of the abovemethod, the unit dose composition is administered IC to patent coronaryvessels or IV to a peripheral vein. In another embodiment, the unit dosecomposition is administered with heparin as described herein.

The above described method for providing coronary angiogenesis is alsobeneficial in human patients that have undergone a myocardial infarction(MI) in one or more coronary arteries. Accordingly, in another aspect,the present invention is also directed to a method for treating a humanpatient for an MI comprising, administering into one or more coronaryvessels or into a peripheral vein of said human patient, a single unitdose composition comprising a therapeutically effective amount of rFGF-2or an angiogenically active fragment or mutein thereof. In the abovemethod, the unit dose composition typically comprises about 0.2 μg/kg toabout 48 μg/kg (or in absolute terms about 0.008 mg to about 7.2 mg) ofa recombinant FGF-2 or an angiogenically active fragment or muteinthereof in a pharmaceutically acceptable carrier. A suitable rFGF-2 foruse in the above-identified method is the rFGF-2 of SEQ ID NO: 2 or anangiogenically active fragment thereof.

In the event of unstable angina or acute myocardial infarction,requiring angioplasty, the same doses of rFGF-2 or angiogenic fragmentor mutein thereof that are disclosed herein would also be useful as anadjunct therapy in treating those conditions. Accordingly, in anotheraspect, the present invention is directed to an improved method fortreating a patient for unstable angina or acute myocardial infarction,requiring angioplasty, the method comprising providing angioplasty tothe patient in need of treatment; the improvement comprisingadministering into one or more coronary vessels or into a peripheralvein of said human patient, a single unit dose composition comprising atherapeutically effective amount of rFGF-2 or an angiogenically activefragment or mutein thereof. In the above method, the unit dosecomposition comprises about 0.2 μg/kg to about 48 μg/kg (or in absoluteterms about 0.008 mg to about 7.2 mg) of a recombinant FGF-2 or anangiogenically active fragment or mutein thereof in a pharmaceuticallyacceptable carrier. A suitable rFGF-2 for use in the above-identifiedmethod is the rFGF-2 of SEQ ID NO: 2 or an angiogenically activefragment thereof.

In any of the above-described methods of the present invention, therFGF-2 or the angiogenically active fragment or mutein thereof isassociated with release of nitric oxide, a recognized smooth muscledilator, which upon administration to the patient causes a sudden dropin the patient's blood pressure. Accordingly, in the methods of thepresent invention, it is preferable to hydrate the patient with IVfluids prior to administering the unit dose of the present invention.Moreover, for safety and tolerability of the unit dose, aggressive fluidmanagement during and after rFGF-2 administration is also preferred.Finally, it is also within the scope of the above described methods toinclude the step of administering an effective amount of aglycosoaminoglycan (also known as a “proteoglycan” or a“mucopolysaccharide”), such as heparin from 0–30 minutes prior toadministering the unit dose composition of the present invention.Typically, the effective amount of glycosaminoglycan (such as heparin)that is administered is about 10–80 U/kg, more typically, about 40 U/kg.However, the total amount of heparin administered to any one patientimmediately prior to dosing generally does not exceed 5,000 U.

Because EDTA is a potent chelator of calcium, which is required fornormal myocardial contraction and cardiac conduction, minimizing theconcentration of EDTA is critical to patient's safety. A concentrationof EDTA less than 100 μg/ml optimized the safety of administration ofrFGF-2 by IC or IV infusion to human patients.

Because a sudden bolus of rFGF-2 is associated with profound hypotensionin animals, the rate of infusion is critical to patient's safety.Administration at 0.5 to 2 ml per minute, typically 1 ml per minute,optimized the safety of administration of rFGF-2 by IC or IV infusion tohuman patients.

A Phase I clinical trial directed to treating human patients for CAD byadministering a single unit dose composition of the present inventionwas conducted and is described in Examples 1–3 herein. In that trial, 66human patients diagnosed with CAD, who satisfied the criteria of Example2 herein, received a single unit dose of rFGF-2 in accordance with themethod of the present invention. Specifically, 52 human patients wereadministered a unit dose of 0.33 μg/kg to 48 μg/kg of rFGF-2 by ICinfusion over about a 20 minute period. Fourteen human patients wereadministered a unit dose of either 18 μg/kg or 36 μg/kg of rFGF-2 by IVinfusion over about a 20 minute period. The 66 treated patients werethen assessed relative to baseline (i.e., prior to treatment with thesingle unit dose), and again at 1 month, 2 months and 6 months aftertreatment with the single unit dose, using three sets of art-recognizedassessment criteria: 1) changes in their exercise tolerance time (ETT);2) the Seattle Angina Questionnaire, which provides an assessment basedupon a mixed combination of objective and subjective criteria; and 3)the measurement of physical changes in the heart as assessed by MRI.

For ETT of the 66 patients of the Phase I clinical trial of Examples 1–3was measured at baseline, and at 1 month, 2 months and 6 months afterdosing (with a single unit dose composition of the invention) using aBruce treadmill protocol. Subjects were excluded from the analysis ifthe treadmill protocol was not the same as used at baseline. Therefore,the number of subjects varied over time. In addition, any patients whohad emergency revascularization were excluded from the analysis. A dosewas considered effective if the mean change in ETT from baselineincreased by greater than 60 seconds. The results of the ETT assessmentare provided in Table 1.

TABLE 1 Exercise Tolerance Time (ETT) - Change from Baseline Change fromChange from Change from FGF-2 Baseline Baseline Baseline Dose Group atOne Month at Two Months at Six Months 0.33 to 2.0 μg/kg IC N = 8 N = 6 N= 5 (N = 16)  45.1 sec 130.0 sec*  60.8 sec (low) (−105 to 180) (19 to240) (−45 to 210) 6.0 and 12 μg/kg IC N = 2 N = 4 N = 2 (N = 8) −24.0sec  −2.5 sec  6.5 sec (mid) (−48 to 0) (−90 to 120) (−0 to 13) 24.0 to48.0 μg/kg IC N = 18 N = 21 N = 16 (N = 28)  51.9 sec 107.9 sec* 133.1sec* (high) (−188 to 399) (−30 to 385) (−195 to 386) 18.0 & 36.0 μg/kgIV N = 12 N = 12 N = 12 (N = 14)  45.1 sec  93.4 sec*  87.5 sec* (−75 to237) (0 to 285) (−60 to 285) ALL GROUPS N = 40 N = 43 N = 35 (N = 66) 45.0 sec  96.0 sec 100.0 sec N = number of subjects; mean; (range inseconds); *= p < 0.05Referring to Table 1, the mean change from baseline at one month wasless than 60 seconds for all dose groups. However, the percentage ofpatients stopping their treadmill test because of angina decreased inall groups over time. At 2 months and 6 months after dosing, the meanchanges from baseline were greater in the high dose IC and IV groups ofpatients than in the low and mid dose IC groups. The persistence ofincreased ETT at 6 months (133.1 sec and 87.5 sec) in the high dose IC(24–48 :g/kg) and IV (18 & 38 :g/kg) groups, respectively, wasunexpected. The greatest mean increases in ETT of 107.9 and 133.1seconds at 2 and 6 months, respectively, occurred in the high dose(24–48 :g/kg) IC group. The IV group exhibited significant meanincreases in ETT of 93.4 seconds and 87.5 seconds, at 2 months and 6months respectively, which was not predicted by the rat and pig animalmodels used herein. Overall, the persistence of the effect (increase inETT) at 2 months and its magnitude for both the IC and IV groups waswholly unexpected.

The 66 human patients of the Phase I clinical trial described inExamples 1–3 herein were also evaluated using the Seattle AnginaQuestionnaire (SAQ). The SAQ is a validated, disease-specific, qualityof life instrument which assesses the following five scales: 1)“exertional capacity”=limitation of physical activity; 2) “diseaseperception”=worry about MI; 3) “treatment satisfaction”; 4) “anginafrequency”=number of episodes and sublingual nitroglycerin usage; and 5)“angina stability”=number of episodes with most strenuous physicalactivity. The possible range of scores for each of the five scales is 0to 100 with the higher scores indicating a better quality of life.Typically, a mean change of 8 points or more between the mean baselinescores (i.e., before treatment) and the post-treatment scores isrecognized as being “clinically significant.” However, in the presentanalysis, a dose was considered “effective” if the mean change in scorefrom baseline increased by greater than 14 points. The reason that 14was chosen (instead of 8) was to allow for the improvement that was seenin the placebo group at 2 months in a clinical trial of another growthfactor—VEGF.

In performing the SAQ evaluation, the patients were categorizedaccording to the same dosage groups that were evaluated for ETT, i.e.,0.33–2.0 μg/kg IC (low) 6.0–12.0 μg/kg IC (mid); 24–48 μg/kg IC (high);and 18 and 36 μg/kg IV. The questionnaire was administered to subjectsin each dosage group at baseline (prior to dosing), and at 2 months and6 months after being administered a single unit dose composition ofrFGF-2 in accordance with the method of the present invention.

The first SAQ scale is “exertional capacity.” The data on exertionalcapacity is summarized in Table 2 herein. As reflected in Table 2,

TABLE 2 Exertional Capacity (EC) - Change from Baseline FGF-2 Changefrom Baseline Change from Baseline Dose Group at Two Months at SixMonths 0.33 to 2.0 μg/kg IC N = 14 N = 7 (N = 16) 15.0* (−25 to 53)23.2* (0 to 53) 6.0 and 12 μg/kg IC N = 7 N = 6 (N = 8) 20.2* (−14 to44)  24.1 (−11 to 69) 24.0 to 48.0 μg/kg IC N = 26 N = 23 (N = 28) 14.6*(−33 to 75) 22.9* (−14 to 75) 18.0 and 36.0 μg/kg IV N = 12 N = 14 (N =14)  10.9 (−8 to 67) 16.5* (−19 to 63) N = number of subjects; mean(range); *= p < 0.05the change from baseline in mean score increased at 2 and 6 months foreach of the three IC dosage groups and at 6 months for all dosage groups(IC and IV). All scores at all dosage levels increased with time ingoing from 2 months to 6 months with the best increases (23.2, 24.1,22.9 and 16.5) relative to baseline being seen at 6 months post-dosing.

The second SAQ scale to be evaluated was “angina stability.” The datasummarizing the angina stability is presented in Table 3 herein.

TABLE 3 Angina Stability (AS) - Change from Baseline FGF-2 Change fromBaseline Change from Baseline Dose Group at Two Months at Six Months0.33 to 2.0 μg/kg IC N = 13 N = 7 (N = 16) 46.2* (0 to 100) 21.4* (0 to50) 6.0 and 12 μg/kg IC N = 7 N = 6 (N = 8) 32.1* (0 to 50)  16.7 (−25to 50) 24.0 to 48.0 μg/kg IC N = 27 N = 24 (N = 28) 34.3* (−25 to 75)17.7* (−25 to 75) 18.0 and 36.0 μg/kg IV N = 12 N = 14 (N = 14) 39.6* (0to 100) 23.2* (0 to 75) N = number of subjects; mean (range); *= p <0.05According to Table 3, the change in score for angina stability increasedrelative to baseline at both 2 and 6 months for each group. Theimprovements in angina stability seen at 2 months after dosing (46.2,32.1, 34.3 and 39.6) were significantly greater than those scores seenat 6 months (21.4, 16.7, 17.7 and 23.2). However, the scores found atboth 2 months and 6 months after dosing showed that all dosages werefound to be effective (>14) in increasing angina stability. Moreover,the magnitude of the increases and their duration for 6 months wereunexpected.

The third SAQ scale to be evaluated was “angina frequency.” The datasummarizing the angina frequency is presented in Table 4 herein.

TABLE 4 Angina Frequency (AF) - Change from Baseline FGF-2 Change fromBaseline Change from Baseline Dose Group at Two Months at Six Months0.33 to 2.0 μg/kg IC N = 14 N = 7 (N = 16) 27.9* (−10 to 80)  12.9 (−40to 50) (low) 6.0 and 12 μg/kg IC N = 7 N = 6 (N = 8) 32.9* (0 to 80) 36.7 (−10 to 90) (mid) 24.0 to 48.0 μg/kg IC N = 27 N = 24 (N = 28)28.9* (−40 to 80) 25.8* (−30 to 80) (high) 18.0 and 36.0 μg/kg IV N = 12N = 14 (N = 14) 20.0* (0 to 90)  11.4 (−30 to 60) ALL GROUPS N = 60 N =51 (N = 66) 27.3 21.4 N = number of subjects; mean (range); *= p < 0.05According to Table 4, the mean patient scores (27.9, 32.9, 28.9 and20.0) for angina frequency increased at 2 months (relative to baseline)by an effective amount (>14) for all dosage groups and for all modes ofadministration (IC or IV). The mean patient scores continued to increaseat 6 months only for the mid dose (6.0–12.0 :g/kg) group, suggesting apeak effect at 2 months post-dosing. However, for the mid dose (6.0–12.0:g/kg) and high dose (24.0–48.0 :g/kg) groups, the changes at 2 monthsand 6 months were similar, suggesting a persistent effect at 6 months onangina frequency.

The fourth SAQ scale to be evaluated was “treatment satisfaction.” Thedata summarizing the angina frequency is presented in Table 5 herein.

TABLE 5 Treatment Satisfaction (TS) - Change from Baseline FGF-2 Changefrom Baseline Change from Baseline Dose Group at Two Months at SixMonths 0.33 to 2.0 μg/kg IC N = 14 N = 7 (N = 16)  8.5* (−19 to 31)  6.3(−25 to 25) (low) 6.0 and 12 μg/kg IC N = 7 N = 6 (N = 8)  17.9 (−13 to44)  19.8 (0 to 63) (mid) 24.0 to 48.0 μg/kg IC N = 27 N = 24 (N = 28)18.8* (−38 to 69)  13.0 (−75 to 63) (high) 18.0 and 36.0 μg/kg IV N = 12N = 14 (N = 14) 19.8* (−13 to 63) 13.4* (−19 to 56) N = number ofsubjects; mean (range); *= p < 0.05According to Table 5, the score for treatment satisfaction increased byan effective amount at 2 months for the mid and high dose IC groups aswell as the IV group. At 2 months post-dosing, only the score for themid dose group IC had a score that was greater than 14, suggesting apeak effect for treatment satisfaction at 2 months.

The fifth SAQ scale to be evaluated was “disease perception.” The datasummarizing the disease perception is presented in Table 6 herein.According to Table 6, the scores for disease perception increased frombaseline to scores of 20.2–29.2 at 2 months and 23.8–34.0 at 6 months.These scores showed that administering a single unit dose composition inaccordance with the method of the present invention was considered to beas effective (or more effective) at 6 months as at 2 months. Thesescores suggest a persistence of the effectiveness of the method of thepresent invention on disease perception out to 6 months followingadministration of a single unit dose composition.

TABLE 6 Disease Perception (DP) - Change from Baseline Change fromBaseline Change from Baseline Dose Group at Two Months at Six Months0.33 to 2.0 μg/kg IC N = 14 N = 7 (N = 16) 29.2* (−8 to 58) 26.2* (0 to42) (low) 6.0 and 12 μg/kg IC N = 7 N = 6 (N = 8) 20.2* (−8 to 50) 30.6*(0 to 58) (mid) 24.0 to 48.0 μg/kg IC N = 27 N = 24 (N = 28) 27.8* (−33to 92) 34.0* (−33 to 100) (high) 18.0 and 36.0 μg/kg IV N = 12 N = 14 (N= 14) 22.9* (−8 to 92) 23.8* (−8 to 75) N = number of subjects; mean(range); *= p < 0.05

Up to 60 of the human patients of the Phase I clinical trial describedin Examples 1–3 herein were also evaluated using resting magneticresonance imaging (MRI) scans of their heart. The resting MRI scans wereperformed on the patients at baseline, and at 1 month, 2 months and 6months after dosing with a single unit dose composition of the presentinvention. The doses were considered “effective” based upon statisticalsignificance (p<0.05). The objective criteria assessed by the restingMRI scans are the following: (1) ejection fraction; (2) myocardialinfarct extent (%); (3) normal wall thickening (4) normal wall motion(%); (5) target wall thickening (%); (6) target wall motion (%); (7)target wall area collateral extent (%); and (8) target area delayedarrival extent (%).

Based upon the resting MRI, no change in “ejection fraction” wasobserved at one month for any one group. The mean change from baselinefor all groups (n=33) at 1 month was an increase of 2.0% (p=0.042). At 2months, the mean change from baseline for the low dose IC group (n=13)was an increase of 8.1% (p=0.007); and for all groups (n=54), the meanchange from baseline was an increase of 3.8% (p=0.001). At 6 months, themean change from baseline for the high dose IC group (n=19) was 5.3%(p=0.023); for the IV group (n=3) was 11.1% (p=0.087); and for allgroups (n=33) was 5.7% (p=0.001).

Based upon the resting MRI, there was no statistically significantchange in the “myocardial infarct extent” (%) for any group, or for allgroups in combination at 1 month, 2 months or 6 months post-dosing. Whenthe normal wall motion (%) and normal wall thickening were assessed,there was no statistically significant change from baseline at 1 month,2 months or 6 months for any one group. However, there was astatistically significant change from baseline in target wall motion forall groups at one (n=60), 2 (n=54) and 2 (n=33) months, which wasreflected as a mean increase from baseline of 2.7% (p=0.015), 4.4%(p=<0.001) and 6.4% (p<0.001), respectively. However, there was also astatistically significant change from baseline in target wall thickeningfor all groups at one (n=60), 2 (n=54) and 2 (n=33) months, which wasreflected as a mean increase from baseline of 4.4% (p=0.015), 6.3%(p=<0.001) and 7.7% (p<0.001), respectively.

The next criteria assessed by MRI was “target area collateral extent”(%). The mean increase from baseline in target area collateral extentfor all groups was highly statistically significant at one month (n=31),2 months (n=27) and 2 months (n=16), wherein the increases were 8.3%(p<0.001), 10.9% (p<0.001) and 11.2% (p<0.001), respectively. Thegreatest collateral extent increases were observed for the low and midIC doses, i.e., at one month (10.4% and 18.3%, respectively), 2 months(14.7% and 18.0%, respectively) and 2 months (16.0% and no value for middose, respectively), which was wholly unexpected. At one month, 2 monthsand 2 months post-dosing, the corresponding % increases in target areacollateral extent that were observed for the IC high dose group were6.3%, 8.0% and 9.0%, respectively.

The final criteria assessed by MRI was “target area delayed arrivalextent” (%). The mean decrease from baseline in target area delayedarrival extent for all groups was highly statistically significant at 1month (n=60), 2 months (n=54) and 6 months (n=34), wherein the decreaseswere −5.8% (p<0.001), −8.3% (p<0.001) and −10.0% (p<0.001),respectively. The greatest target area delayed extent decreases wereobserved for the low dose IC group, which was also highly unexpected.

Thus, providing CAD patients with a single IC or IV infusion of rFGF-2in accordance with the present invention provided the patients with astatistically significant physical improvement as objectively measuredby MRI and other conventional criteria.

Pharmacokinetics and Metabolism

The molecular structure of FGF-2 contains a positively charged tail thatis known to bind to proteoglycan chains (heparin and heparin-likestructures) on cell surfaces and on the endothelial wall of thevasculature. See Moscatelli, et al., “Interaction of Basic FibroblastGrowth Factor with Extracellular Matrix and Receptors,” Ann. NY Acad.Sci., 638:177–181 (1981).

The kidneys and liver are the major organs for the elimination ofrFGF-2. In particular, the kidneys have a protein cutoff of about 60 kDand thus retain serum albumin (MW 60 kD). However, FGF-2 (146 residues)has a molecular weight of about 16.5 kD. Accordingly, renal excretion isto be expected. In a radiolabelled biodistribution study of commerciallyavailable bovine FGF-2 (bFGF-2), both the liver and the kidney wereshown to contain high counts of the radiolabelled bFGF-2 at 1 hour afterIV or IC injection. In a published study, wherein another recombinantiodinated form of bFGF-2 was given to rats, the liver was identified asthe major organ of elimination. Whalen et al., “The Fate ofIntravenously Administered bFGF and the Effect of Heparin,” GrowthFactors, 1:157–164 (1989). It is also known that FGF-2 binds in thegeneral circulation to α₂-macroglobulin and that this complex isinternalized by receptors on the Kupffer cells. Whalen et al. (1989) andLaMarre et al., “Cytokine Binding and Clearance Properties ofProteinase-Activated Alpha-2-Macroglobulins,” Lab. Invest., 65:3–14(1991). Labelled FGF-2 fragments were not found in the plasma, but theywere found in the urine and corresponded in size to intracellularbreakdown products.

In preclinical testing, we determined the pharmacokinetics of rFGF-2(SEQ ID NO: 2) after intravenous (IV) and intracoronary (IC)administration in domestic Yorkshire pigs, and after IV administrationdosing in Sprague Dawley (“SD”) rats. The pig models demonstrated linearpharmacokinetics (0.65 μg/kg–20 μg/kg) IC and IV. The terminal half-lifeof the FGF-2 in the pig model was 3–4 hours. The rat models demonstratedlinear pharmacokinetics over the range of 30–300 μg/kg IV. The terminalhalf-life of the FGF-2 in the rat model was 1 hour. Both species showedplasma concentration suggesting a two-compartment model.

Likewise, in humans, the FGF-2 plasma concentrations after IV and/or ICinfusion followed a biexponential curve with an initial steep slope andconsiderable decrease over several log scales (the distribution phase)during the first hour, followed by a more moderate decline (theelimination phase). FIG. 1A provides a plasma concentration versus timecurve showing these phases in humans after IC administration of rFGF-2of SEQ ID NO: 2 as a function of each of the following eight doses: 0.33μg/kg, 0.65 μg/kg, 2 μg/kg, 6 μg/kg, 12 μg/kg, 24 μg/kg, 36 μg/kg, and48 μg/kg of lean body mass (LBM). FIG. 1A shows the plasma doselinearity for the eight doses of rFGF-2 that were administered by ICinfusion over a twenty minute period. FIG. 1A also shows a biphasicplasma level decline, i.e., a fast distribution phase during the firsthour, followed by an elimination phase with an estimated T_(1/2) of 5–7hours. The plasma concentrations of FGF-2 of SEQ ID NO: 2 weredetermined by a commercially available ELISA (R&D Systems, MinneapolisMinn.) that was marketed for analysis of human FGF-2. The ELISA assayshowed 100% cross-reactivity with the rFGF-2 of SEQ ID NO: 2. Othermembers of the FGF family, as well as many other cytokines, were notdetected by this assay. Further, heparin does not interfere with theassay.

FIG. 1B is a plot of the mean FGF-2 plasma concentration as a functionof time for 18 μg/kg and 36 μg/kg rFGF-2 administered IV, as compared to36 μg/kg rFGF-2 administered IC. The plasma concentration versus timeprofiles in FIG. 1B for the 36 μg/kg doses by the IV and IC routes aresuperimposible. However, a first-pass effect with the IC route is noteliminated.

FIG. 2 is a plot of mean FGF-2 area under the curve (AUC) in pg*min/mlcorresponding to FIGS. 1A and 1B. FIG. 2 shows the dose linearity ofsystemic rFGF-2 exposure (AUC) following IC or IV infusion. Inparticular, FIG. 2 shows that the systemic exposure to rFGF-2 followingadministration by the IC and IV routes is substantially similar.

FIG. 3 is a plot of individual human patient plasma clearance (CL)values (ml/min/kg) as a function of the time of heparin administrationin “minutes prior to rFGF-2 infusion.” FIG. 3 shows the influence oftiming of heparin administration on FGF-2 plasma clearance (CL).Although FIG. 3 shows that administering heparin up to 100 minutes priorto rFGF-2 decreases FGF-2 clearance, the preferred time foradministering heparin is from 0–30 minutes prior the rFGF-2administration, wherein the effect of the heparin on decreasing FGF-2clearance is greatest.

FIG. 4 is a plot individual human patient rFGF-2 dose normalized areaunder curves (AUCs) as a function of the time of heparin administrationin “minutes prior to rFGF-2 infusion” and shows the influence of timingof heparin administration on rFGF-2 AUC. FIG. 4 shows that the greatestAUC/dose was achieved when an effective amount of a glycosoaminoglycan,such as heparin, was preadministered within 30 minutes or less of ICrFGF-2 infusion, more preferably within 20 minutes or less of IC or IVrFGF-2 infusion. Typically, an effective amount of a glycosoaminoglycanis 10–80 U/kg heparin.

The mean pharmacokinetic parameters for rFGF-2 in humans as a functionof dosage and mode of administration are summarized in Table 7 herein.Referring to Table 7, the T½ for FGF-2 in humans was determined to rangefrom 2.2±3.7 hours at low dose (0.33–2.0 μg/kg) IC to 7.0±3.5 hours at adose of 18–36 μg/kg IV; given the limitations of the assay, the terminalhalf-life is estimated at 5–7 hours for all groups. The clearances ofFGF-2 ranged from 13.2 to 18.2 L/hour/70 kg man. Finally, the steadystate volume (V_(ss)) was determined to range from 11.3±10.4 L/70 kg manto 16.8±10.7 L/70 kg man.

TABLE 7 Mean rFGF-2 PK Parameters in Humans FGF-2 CL V_(ss) Dose μg/kg NRoute (L/hr/70 kg) t_(1/2) (h) (L/70 kg) 0.3–2   16 IC 18.2 ± 13.4 2.2 ±3.7 11.3 ± 10.4  6–12 8 IC 13.2 ± 7.3  3.1 ± 2.5 12.1 ± 4.9  24–48 28 IC14.7 ± 8.3  6.3 ± 1.8 16.8 ± 10.7 18–36 14 IV 13.9 ± 7.9  7.0 ± 3.5 16.4± 8.6 

Although the binding of FGF-2 to heparin-like structures is strong(dissociation constant ˜2×10⁻⁹ M), the binding of FGF-2 to a specifictyrosine kinase receptor is approximately 2 orders of magnitude higher(dissociation constant ˜2×10⁻¹¹ M). Moscatelli et al., (1991). Thus,without being bound to any theory, the complexation of rFGF-2 with aglycosoaminoglycan, such as a heparin, might increase signaltransduction and mitogenesis, and/or protect the rFGF-2 from enzymaticdegradation.

Further aspects of the invention for the administration of FGF-2 asdisclosed herein include, but are not limited to: to improve exercisecapacity as measured by ETT treadmill analysis; to improve exercisecapacity as measured by exertional capacity domain of the SAQ; to reducethe frequency of angina; and to increase perfusion as measured by MRI.In particular exercise capacity was significantly improved in patientswith congestive heart failure.

The following examples are offered by way of illustration and not by wayof limitation.

EXAMPLE 1 Unit Dose of rFGF-2 Employed in the Phase I Clinical Trial

The rFGF-2 of SEQ ID NO: 2 was formulated as a unit dose andpharmaceutical composition and administered to rats, pigs and ultimatelyto humans in the Phase I clinical trial referenced herein. The variousformulations are described below.

-   The rFGF-2 Unit Dose was provided as a liquid in 3 cc type I glass    vials with a laminated gray butyl rubber stopper and red flip-off    overseal. The rFGF-2 unit dose contained 1.2 ml of 0.3 mg/ml rFGF-2    of SEQ ID NO: 2 in 10 mM sodium citrate, 10 mM monothioglycerol, 1    mM disodium dihydrate EDTA (molecular weight 372.2), 135 mM sodium    chloride, pH 5.0. Thus, in absolute terms, each vial (and unit dose)    contained 0.36 mg rFGF-2. The vials containing the unit dose in    liquid form were stored at 2° to 8° C.-   The rFGF diluent was supplied in 5 cc type I glass vials with a    laminated gray butyl rubber stopper and red flip-off overseal. The    rFGF-2 diluent contains 10 mM sodium citrate, 10 mM    monothioglycerol, 135 mM sodium chloride, pH 5.0. Each vial    contained 5.2 ml of rFGF-2 diluent solution that was stored at 2° to    8° C.-   The rFGF-2 Pharmaceutical Composition that was infused was prepared    by diluting the rFGF-2 unit dose with the rFGF diluent such that the    infusion volume is 10–40 ml. In order to keep the EDTA concentration    below a preset limit of 100 μg/ml, the total infusion volume was    increased to a maximum of 40 ml when proportionately higher absolute    amounts of FGF-2 were administered to patients with higher body    weights.

EXAMPLE 2 Selection Criteria for Patients with Coronary Artery Diseasefor Treatment with rFGF-2

The following selection criteria were applied to Phase I patients withcoronary artery disease, whose activities were limited by coronaryischemia despite optimal medical management, and who were not candidatesfor approved revascularization therapies:

Inclusion criteria: Subject is eligible if:

-   -   Male or female, greater than or equal to 18 years of age    -   Diagnosis of coronary artery disease (CAD)    -   Suboptimal candidates for approved revascularization procedures,        e.g., angioplasty, stents, coronary artery bypass graft (CABG)        (or refuses those interventions)    -   Able to exercise at least three minutes using a modified Bruce        protocol and limited by coronary ischemia    -   Inducible and reversible defect of at least 20% myocardium on        pharmacologically stressed thallium sestamibi scan    -   CBC, platelets, serum chemistry within clinically acceptable        range for required cardiac catheterization    -   Normal INR, or if anticoagulated with Coumadin, INR<2.0    -   Willing and able to give written informed consent to participate        in this study, including all required study procedures and        follow-up visits

Exclusion criteria: Subject is not eligible if:

-   -   Malignancy: any history of malignancy within past ten years,        with the exception of curatively treated basal cell carcinoma.    -   Ocular conditions: proliferative retinopathy, severe        non-proliferative retinopathy, retinal vein occlusion, Eales'        disease, or macular edema or fluduscopy by ophthalmologist:        history of intraocular surgery within 2 months    -   Renal function: creatinine clearance below normal range adjusted        for age; protein>250 mg or microalbumin>30 mg/24 h urine    -   Class IV heart failure (New York Heart Association)    -   Ejection fraction<20% by echocardiogram, thallium scan, MRI or        gated pooled blood scan (MUGA)    -   Hemodynamically relevant arrhythmias (e.g., ventricular        fibrillation, sustained ventricular tachycardia)    -   Severe valvular stenosis (aortic area<1.0 cm², mitral area<1.2        cm²), or severe valvular insufficiency    -   Marked increase in angina or unstable angina within three weeks    -   History of myocardial infarction (MI) within three months    -   History of transient ischemic attack (TIA) or stroke within 2        months    -   History of CABG, angioplasty or stent within 2 months    -   History of treatment with transmyocardial laser        revascularization, rFGF-2, or vascular enodothelial growth        factor (VEGF) within 2 months    -   Females of child-bearing potential or nursing mothers    -   Any pathological fibrosis, e.g., pulmonary fibrosis, scleroderma    -   Known vascular malformation, e.g., AV malformation, hemangiomas    -   Coexistence of any disease which might interfere with assessment        of symptoms of CAD, e.g., pericarditis, costochondritis,        esophagitis, systemic vasculitis, sickle cell disease    -   Coexistence of any disease which limits performance of modified        Bruce protocol exercise stress test, e.g., paralysis or        amputation of a lower extremity, severe arthritis or lower        extremities, severe chronic obstructive pulmonary disease (COPD)    -   Participation in clinical trials of investigational agents,        devices or procedures within thirty days (or scheduled within 60        days of study drug)    -   Known hypersensitivity to rFGF-2 or related compounds    -   Any condition which makes the subject unsuitable for        participation in this study in the opinion of the investigator,        e.g., psychosis, severe mental retardation, inability to        communicate with study personnel, drug or alcohol abuse.

EXAMPLE 3 Phase I Clinical Study on Recombinant FGF-2 (SEQ ID NO: 2)Administered to Humans

The Phase I CAD trial of this example is an open label, dose escalationstudy of recombinant fibroblast growth factor-2 (rFGF-2) for safety,tolerability and pharmacokinetics. The study was conducted at 2 sites:Beth Israel Deaconess Hospital (Harvard) in Boston, Mass. and EmoryUniversity Hospital in Atlanta, Ga. Enrollment is complete. Subjectswere treated with a single infusion of rFGF-2 on Day 1 and followed for360 days; follow-up is not yet complete in some subjects.

The subject population consists of patients with advanced CAD who areexercise limited by coronary ischemia and are considered suboptimalcandidates for (or do not want to undergo) one of the establishedrevascularization procedures (e.g., CABG, angioplasty—with or withoutstent). The major exclusion criteria were history or suspicion ofmalignancy, uncompensated heart failure or left ventricular ejectionfraction<20%, renal insufficiency or proteinuria, and various ocularconditions (e.g., proliferative diabetic retinopathy, severenon-proliferative retinopathy).

Sixty-six subjects have received rFGF-2 of SEQ ID NO: 2 in this trial:52 received the rFGF-2 as an IC infusion and fourteen received it as anIV infusion. Each subject was observed in the hospital for at leasttwenty-four hours, and then followed as an outpatient for 360 days withfollow-up visits (Days 15, 29, 57, 180 and 360). At least four subjectswere studied at each dose; if no subject experienced dose-limitingtoxicity as defined by the protocol within 2 days, the dose wasescalated. The drug was administered as a single 20 minute infusiondivided between 2 major sources of coronary blood supply (IC), usingstandard techniques for positioning a catheter into the patient'scoronary artery (such as already employed in angioplasty) or in aperipheral vein (IV). The doses in μg/kg of rFGF-2 administered IC (andthe number of patients) were 0.33 (n=4), 0.65 (n=4), 2.0 (n=8), 6.0(n=4), 12.0 (n=4), 24 (n=8), 36 (n=10) and 48 (n=10) of rFGF-2 of SEQ IDNO: 2. The doses in μg/kg of rFGF-2 administered IV (and the number ofpatients) were 18.0 (n=4) and 36.0 (n=10) or rFGF-2 of SEQ ID NO: 2.

Angina frequency and quality of life was assessed by the Seattle AnginaQuestionnaire (SAQ) at a baseline (before rFGF-2 administration) and at2 months and 6 months after rFGF-2 administration. Exercise tolerancetime (ETT) was assessed by the treadmill test at 1, 2, and 6 months.Rest/exercise nuclear perfusion and gated sestamibi-determined restejection fraction (EF), and resting magnetic resonance imaging (MRI)were assessed at baseline, and at 1 month, 2 months and 6 months postrFGF-2 administration. MRI measurements which were thought toobjectively measure changes in % in cardiac function and perfusionincluded: (1) ejection fraction; (2) myocardial infarct extent (%); (3)normal wall thickening (4) normal motion (%); (5) target wall thickening(%); (6) target wall motion (%); (7) target wall area collateral extent(%); and (8) target area delayed arrival extent (%).

If one of four subjects experienced dose-limiting toxicity (as definedby the protocol), four additional subjects were studied at that dose; ifnone experienced toxicity, the dose was escalated and another group wasstudied. The maximally tolerated dose (MTD) was defined as the IC dosewhich was tolerated by 9/10 subjects, i.e., 36 μg/kg IC.

Careful fluid management pre-infusion was prescribed using a Swan-Ganzcatheter and vital signs were monitored frequently during dosing.Heparin was administered IV prior to the infusion of rFGF-2 in allgroups. The EDTA concentration was less than 100 μg/ml in the unit dosecomposition. Volume of study drug administered varied with dose andsubject's weight, and ranged from 10 ml at lower doses to 40 ml athigher doses.

Preliminary Results

The results presented here are unaudited and are based on a thirdinterim analysis for 66 subjects with 2 months follow-up for all groups(1–10) and the serious adverse events (SAE) report of 29 Jul. 1999 fromChiron Drug Safety. Data collection for the last visit (Day 360) andfinal analysis is in progress.

The starting dose of 0.33 μg/kg IC was escalated over eight sequentialgroups to 48 μg/kg IC, at which dose 2 of ten subjects experienceddose-limiting toxicity (hypotension) as defined by the protocol.Hypotension was manageable with fluids alone in all subjects (novasopressors or assistive devices). At 36 μg/kg IC, only 1 of 10subjects had dose-limiting toxicity which defined this dose as themaximally tolerated dose (MTD). Two additional groups were studied by IVinfusion; four subjects of half the MTD (18 μg/kg) and ten subjects atthe MTD (36 μg/kg).

Hypotension was dose-limiting in humans, as predicted by the animalmodel in Yorkshire pigs. However, 36.0 μg/kg rFGF-2 IC was tolerated inhumans; whereas in pigs, 20.0 μg/kg rFGF-2 IC caused profoundhypotension in one of 2 animals. Better tolerability in humans wasattributed to aggressive fluid management and absence of generalanesthesia.

As of 29 Jul. 1999, thirty-three serious adverse events (SAEs) haveoccurred in 24/66 subjects, but were not dose-related. Fifteen (15) SAEswere considered at least possibly related to rFGF-2; whenever there wasa difference between relatedness assigned by the investigator and themedical monitor, the more conservative relationship was assigned. SAE'swere multiple in five subjects: 01103 (0.33 μg/kg IC), 01106 (0.65 μg/kgIC), 01113 (2.0 μg/kg IC), 01137 (36.0 μg/kg IV), 02101 (0.65 μg/kg IC).

The most frequent treatment-emergent adverse events (AEs) on Day 1 weretransient systolic hypotension and transient bradycardia. Thehypotension was dose-dependent and occurred more frequently at dosesgreater than or equal to (≧) 24 μg/kg IC; bradycardia was notdose-dependent. Other adverse events (AEs) which were deemed at leastpossibly related and appeared dose-related occurred within the firstseveral days or week post infusion and included chest pain, shortness ofbreath, insomnia, anxiety, and nausea. These events were mild tomoderate in severity, and most did not require specific intervention.

When administered IC, the drug was administered over approximately 20minutes as a single infusion divided between 2 major sources of coronaryblood supply (IC), using standard techniques for positioning a catheterinto the patient's coronary artery (such as already employed inangioplasty). When administered IV, the drug was administered as aninfusion over 20 minutes into a peripheral vein.

The preliminary safety results indicate that serious events were notdose related. Thus far, of the eight IC dosage groups, there were threedeaths in the lower dosage groups, i.e., at 0.65 μg/kg (Day 23), at 2.0μg/kg (Day 57) and at 6.0 μg/kg (Day 63), and one death in the highestdose group, i.e., at 48.0 μg/kg (approximately 4 months post-dosing).Three of the deaths were cardiac; one death was due to a large B celllymphoma that was diagnosed three weeks after dosing in the patient ingroup 4 (6.0 μg/kg) who patient died at 2 months post-dosing.

Acute myocardial infarction (MI) occurred in four patients, i.e., onepatient from each of groups 1 (0.33 μg/kg), 3 (2.0 μg/kg), 4 (6.0 μg/kg)and 7 (36.0 μg/kg). Multiple MIs occurred in 2 patients, i.e., one fromgroup 1 (0.33 μg/kg) and one from group 3 (2.0 μg/kg). Emergencyrevascularization procedures (CABG or angioplasty with or withoutsstent) were performed during follow-up in 4 patients: one each fromgroups 1 (0.33 μg/kg), 3 (2.0 μg/kg), 4 (6.0 μg/kg), and 7 (36.0 μg/kg).

Acute hypotension, seen at higher doses during or just subsequent toinfulsion, was managed by administration of IV fluids without need for avasopressor. The maximally tolerated dose (MTD) in humans was defined as36 μg/kg IC. (In contrast, in pigs, the MTD was 6.5 μg/kg IC.) Doses ofrFGF-2 up to 48 μg/kg IC were administered in human patients withaggressive fluid management, but were defined by the protocol as “nottolerated” due to acute and/or orthostatic hypotension in 2 out of tenpatients. The terminal half-life of the infused rFGF-2 was estimated at5 to 7 hours.

The human patients in this study that were treated with a single IC orIV infusion of rFGF-2 of SEQ ID NO: 2 exhibited a mean increase in ETTof 1.5 to 2 minutes. See Table 1. This is especially significant becausean increase in ETT of greater than (>) 30 seconds is consideredsignificant and a benchmark for evaluating alternative therapies, suchas angioplasty. The angina frequency and quality of life, as measured bySAQ, showed a significant improvement at 2 months in all five subscalesfor the 66 patients (n=66) tested. See Tables 2–6. In Tables 2–6, a meanchange of 14 or more was considered “clinically significant.” When 33human CAD patients were assessed by resting cardiac magnetic resonanceimaging (MRI) at baseline, and at 1, 2, and 6 months after receiving asingle unit dose composition of the present invention by IC or IVroutes, a highly statistically significant increase was observed intarget wall thickening, target wall motion and target area collateralextent; a highly statistically significant decrease was observed intarget area delayed arrival extent; and no statistically significantchanges were observed in normal wall motion, normal wall thickening ormyocardial infarct extent.

In addition to the above criterion (i.e., ETT SAQ, MRI), a treatment isconsidered very successful if the angiogenic effects last at least 2months. In the present Phase I study, the unexpectedly superiorangiogenic effects were observed to last up to 6 months in some patientsin all dosage groups. Based upon the results already obtained, it isexpected that the angiogenic effects may last twelve months or more butdo last at least 2 months in the patients, at which time the procedurecould be repeated, if necessary.

EXAMPLE 4 Unit Dose and Pharmaceutical Composition of rFGF-2 for thePhase H Human Clinical Trial

-   The rFGF-2 of SEQ ID NO: 2 was formulated as a unit dose    pharmaceutical composition for administration to humans in the Phase    II clinical trial referenced herein. The various formulations are    described below.-   The rFGF-2 Unit Dose was prepared as a liquid in 5 cc type I glass    vials with a laminated gray butyl rubber stopper and red flip-off    overseal. The rFGF-2 formulation contains 0.3 mg/ml rFGF-2 of SEQ ID    NO: 2 in 10 mM sodium citrate, 10 mM monothioglycerol, 0.3 mM    disodium dihydrate EDTA (molecular weight 372.2), 135 mM sodium    chloride, pH 5.0. Each vial contained 3.7 ml of rFGF-2 drug product    solution (1.11 mg rFGF-2 per vial). The resulting unit dose in    liquid form is stored at less than −60° C. The above described unit    dose is diluted with the “rFGF-2 placebo.” Depending on the size of    the patient, the contents of several of the vials may be combined to    produce a unit dose of 36 μg/kg for the Phase II study.-   The rFGF-2 placebo is supplied as a clear colorless liquid in 5 cc    type I glass vials with a laminated gray butyl rubber stopper and    red flip-off overseal. The rFGF-2 placebo is indistinguishable in    appearance from the drug product and has the following formulation:    10 mM sodium citrate, 10 mM monothioglycerol, 0.3 mM disodium    dihydrate EDTA (molecular weight 372.2), 135 mM sodium chloride, pH    5.0. Each vial contains 5.2 ml of rFGF-2 placebo solution. Unlike    the unit dose, the rFGF-2 placebo is stored at 2° to 8° C.-   The rFGF-2 Pharmaceutical Composition that is infused is prepared by    diluting the rFGF-2 unit dose with the rFGF diluent such that the    infusion volume is 20 ml for Phase II.

EXAMPLE 5 Phase II Clinical Study on rFGF-2 (SEQ ID NO: 2) Administeredto Humans to Treat Coronary Artery Disease

Primary Objective

To compare the effect of a single, IC infusion of rFGF-2 versus placeboon exercise capacity, as measured by the change in exercise tolerancetest (ETT) time from baseline (during the screening period) to 90 days.

Secondary Objectives

-   To evaluate the safety of rFGF-2, as measured by AEs and changes in    laboratory parameters.-   To confirm the pharmacokinetics (PK) of rFGF-2 from the Phase I    study.-   To evaluate the effect of rFGF-2 on:    -   Change in ETT time from baseline to 180 days.    -   Changes from baseline in quality of life (QoL): perceived angina        as measured by the Seattle Angina Questionnaire (SAQ) and        general well-being, as measured by the Short Form-36 (SF-36) at        90 and 180 days.    -   Changes from baseline in the size of the ischemic area at rest        and with pharmacologic stress with dipyridamole by        thallium/sestamibi scans at 90 and 180 days.-   In a subset of subjects, to evaluate the effect of rFGF-2 on EF,    target wall motion, and wall thickness and perfusion by magnetic    resonance imaging (MRI) scan.    Investigational Plan    Overall Study Design and Plan

This clinical trial was designed as a phase 2, multicenter,double-blind, placebo-controlled study of rFGF-2 in 300 subjects withCAD. Subjects who met all eligibility criteria were randomly assigned toreceive placebo or one of three doses of rFGF-2 (approximately 75subjects per arm). Doses were 0 (placebo), 0.3, 3.0, and 30.0 μg/kgbased on actual body weight. Study drug was to be administered as asingle IC infusion over 20 minutes during cardiac catheterization.Subjects were monitored in the hospital for at least 6 hours postdose atthe site, and then followed at specified intervals over 180 days.Long-term safety was assessed in a separate extension protocol usingtelephone contacts and questionnaires for an additional 6 months.

Inclusion Criteria

The following inclusion criteria were required for study entry:

-   Men or women≧18 years of age.-   Diagnosis of CAD, as defined by >60% stenosis of a major coronary    artery by coronary angiography.-   Ejection fraction≧30% by an accepted imaging technology    (ventriculogram, MRI, first pass on single photon emission computed    tomography [SPECT]) scan, echocardiogram [ECHO] or multigated [MUGA]    nuclear assessment).-   Symptoms of angina or angina equivalent.-   Relegated to non-invasive therapy for CAD under the care of a    physician.-   Not a candidate for standard surgical or catheter-based    revascularization procedures as assessed by a physician.-   No evidence of malignancy on mammography within 12 months (females).-   Pelvic exam with cervical smear within 1 year of screening for all    females.-   Sigmoidoscopy within 5 years for all subjects ≧50 years.-   Annual rectal exam with stool guaiac for subjects ≧40 years.-   Able to exercise on baseline treadmill exercise testing for at least    3 minutes but not longer than 13 minutes using a modified Bruce    protocol, and limited by signs or symptoms of ischemia. Subjects had    to complain of some degree of angina or anginal equivalent or have≧1    mm ST segment depression during the course of the ETTs. Duplicate    baseline tests were performed at least 24 hours but not greater than    2 weeks apart, and the difference between the two tests had to be    ≦20% of the average of the two tests.-   Inducible and reversible ischemic defect of moderate or greater size    involving at least half the area of one major myocardial territory    (anterior, inferior, lateral, or septal) on a rest/stressed    thallium/sestamibi scan, or multiple inducible and reversible    ischemic defects in multiple myocardial territories, the sum total    of which involves the equivalent of at least half the area of one    major myocardial territory on a rest/stressed thallium/sestamibi    scan within 30 days prior to randomization.-   Complete blood count (CBC), platelets, serum chemistry, prothrombin    time, and urinalysis within clinically acceptable ranges for cardiac    catheterization within 30 days prior to randomization.-   Protein on a urine sample negative or trace within 30 days prior to    randomization.-   Serum creatinine ≦2.0 mg/dL within 30 days prior to randomization.-   Willing and able to give written informed consent to participate in    this study, including all required study procedures and follow-up    visits.-   Prostate specific antigen (PSA) within 30 days prior to    randomization (males) conforming to the following age-specific    ranges:

Age PSA (ng/mL) <40 years <2.0 40–49 years <2.7 50–59 years <3.7 60–69years <5.1 70–79 years <7.0 ≧80 years <7.2

-   No evidence of malignancy on chest x-ray within 30 days prior to    randomization-   No evidence or suspicion of malignancy as assessed by complete    history and physical exam (performed according to American Cancer    Society guidelines) within 30 days of randomization.-   Confirmation on Study Day 1 by cardiac catheterization that the    subject's cardiovascular anatomy is not suitable for treatment with    an invasive procedure according to the opinion of the principal    investigator or another study physician at the site.    Exclusion Criteria-   Malignancy: History or suspicion of malignancy within the past 10    years, with the exception of curatively treated basal cell    carcinoma, squamous cell carcinoma of the skin in sun-exposed areas,    or carcinoma of the cervix.-   Renal conditions:    -   Renal insufficiency, as defined by serum creatinine >2.0 mg/dL.    -   Proteinuria, as defined by 1+ or greater protein on dipstick.-   Ocular conditions:    -   Proliferative retinopathy, moderate or severe nonproliferative        retinopathy.    -   Retinal vein occlusion.    -   Age-related maculopathy with choroidal neovascularization.    -   Macular edema on funduscopy by an ophthalmologist.    -   Intraocular surgery within 4 months.-   Cardiovascular conditions:    -   Severe aortic stenosis, ie, area<1.0 cm².    -   Unstable angina within 3 weeks (Braunwald, 1984).    -   CABG, angioplasty, transient ischemic attack, or stroke within 4        months.    -   Myocardial infarction within 3 months.    -   Treatment with transmyocardial laser revascularization within 1        year of screening.    -   Current treatment with external counterpulsation.    -   Past participation in any therapeutic angiogenesis trial with        any investigational agent unless it could be demonstrated that        the subject definitely received placebo.    -   Diagnosis of primary pulmonary hypertension or restrictive or        obstructive cardiomyopathy.-   General medical conditions:    -   Pregnancy or nursing mothers.    -   Any pathological fibrosis, eg, pulmonary fibrosis, scleroderma.    -   Known vascular malformation, eg, arteriovenous malformation,        hemangiomas>3 mm.    -   Participation in clinical trials of other investigational        agents, IC devices or procedures, for which follow-up visits had        not been completed.    -   History of organ transplantation.    -   Any combined condition which made the subject unsuitable for        participation in this study in the opinion of the investigator,        eg, concurrent medical illness which limits life expectancy        to<12 months, psychosis, severe mental retardation, inability to        communicate with study personnel, drug or alcohol abuse.        Removal of Subjects from Therapy or Assessment

A subject could withdraw consent to participate in the study at any timewithout prejudice. Additionally, the investigator could withdraw asubject if, according to clinical judgement, it was in the best interestof the subject or if the subject could not comply with the protocol.

If a subject who met all inclusion and exclusion requirements andreceived study drug on Day 1 subsequently withdrew from the study, thetests and evaluations listed for the day 180 termination visit werecarried out whenever possible.

If a subject developed an AE that the investigator believed was severeenough to interrupt study drug administration for >10 minutes, dosingwas discontinued and the subject was not to be allowed to receivefurther study drug treatment. The subject was to receive medicaltreatment as determined by the investigator, remain under observationuntil the AE resolved or became stable, and was to be followed throughday 180.

Treatments Administered

Subjects were randomly assigned to receive placebo or 0.3, 3.0, or 30.0μg/kg rFGF-2. The study drug was to be administered as an infusion of 20mL over 20 minutes divided between two patent coronary vessels orgrafts, using a calibrated, precision, infusion pump.

Identity of Investigational Product

The rFGF-2 used in this study was a 146 amino acid, non-glycosylated,monomeric, 16.5 kDa protein that was expressed in genetically engineeredyeast. The rFGF-2 drug product was supplied as a clear, colorless liquidin 5-mL, type I, glass vials with a laminated, gray, butyl stopper andred, flip-off overseal. The rFGF-2 formulation contained 0.3 mg/mLrFGF-2 in 10 mM sodium citrate, 10 mM monothioglycerol, 0.3 mM disodiumdihydrate EDTA (molecular weight 372.2), 135 mM sodium chloride, pH 5.0.Each vial contained 3.7 mL of rFGF-2 drug-product solution (1.11 mgrFGF-2 per vial). The rFGF-2 drug-product vials were stored at −60° C.or less. The rFGF-2 was diluted with placebo according to the subjects'actual body weight.

The placebo was supplied as a clear, colorless liquid in 5-mL, type I,glass vials with a laminated, gray, butyl stopper and red, flip-offoverseal. The placebo was indistinguishable in appearance from the drugproduct; it contained 10 mM sodium citrate, 10 mM monothioglycerol, 0.3mM disodium dihydrate EDTA (molecular weight 372.2), 135 mM sodiumchloride, pH 5.0. Each vial contained 5.2 mL of placebo solution. Theplacebo vials were stored at 2 to 8° C.

Selection of Doses in the Study

The doses selected were those that bracketed a range of doses for whichpreclinical and early clinical data suggested the best probability ofefficacy. The safety of the highest dose (30.0 μg/kg) was supported bythe phase 1 trial results reported in Example 3.

Subjects typically received a single IV bolus of heparin between 10 and20 minutes prior to infusion of study drug in order to minimize the riskof thrombosis related to the duration of time the catheter was in place.

Efficacy and Safety Variables

Efficacy and Safety Measurements Assessed and Flowchart

The primary efficacy variable was the change in exercise capacity asmeasured by ETT time at Day 90. Secondary efficacy variables includedthe change in ETT time at Day 180; the change in QoL as measured by theangina frequency score (AFS), treatment satisfaction score (TSS),exertional capacity score (ECS), and disease perception score (DPS) ofthe SAQ, and the physical and mental components of the SF-36 at Days 90and 180; the change in ischemic area at rest and with pharmacologicstress by thallium/sestamibi scans at Days 90 and 180; changes in EF,targeted wall thickness and motion, and perfusion by MRI at Days 90 and180 in a subset of subjects.

Other analysis variables added at the time that the statistical analysisplan was implemented included time to onset of angina, time to onset of1-mm ST segment depression, and changes from baseline in rate-pressureproduct at onset of angina, in rate-pressure product at peak exercise,and in rate-pressure product at 1-mm ST segment depression at Days 90and 180. Changes in the New York Heart Association (NYHA) classificationand the Canadian Cardiovascular Class (CCC) were analyzed. Thepercentage of subjects with ≧60 seconds increase in ETT time(“responder”) and of subjects with <60 seconds increase in ETT time(“non-responder”) was analyzed for each group.

The Canadian Cardiovascular Classification is based on a classificationscheme ranging from Class 0 to Class IV. To be classified in: Class 0, apatient does not experience angina or anginal equivalent symptoms; ClassI, with ordinary physical activity symptoms occur only with strenuous,rapid, or prolonged exertion at work or recreation; Class II, a patientexperiences slight limitation of ordinary activity due to angina; ClassIII, a patient experiences marked limitation of activity due to angina;and Class IV, a patient develops angina at rest or with any physicalactivity.

The SAQ is a validated, disease-specific, self-administeredquestionnaire with 5 scales: angina stability scale (ASS), anginafrequency scale (AFS), exercise capacity scale (ECS), treatmentsatisfaction scale (TSS), and disease perception scale (DPS) (SpertusJA, et al.). The ASS was not included in the analysis of this trial asit refers to a 4 week interval which was not relevant to the evaluationperiods. Each component comprises a scale from 1 to 100; lower scoresare associated with worse symptoms; ≧8 point changes are consideredclinically relevant. The SF-36 is a validated, general, quality-of-life(QoL) instrument with 10 scales and two summary component scales: aphysical component summary scale (PCSS) and a mental component summaryscale (MCSS).

Nuclear imaging results were analyzed using a validated semiquantitativegrading system in a 20-segment left ventricular model (Berman D S, etal.). The perfusion of each segment was graded on a five-point scale:0=normal, 1=slightly reduced, 2=moderately reduced, 3=severely reduced,and 4=absent. A segment was determined to have a reversible defect ifthe assigned abnormal regional grade at stress decreased or normalizedon the rest images (reversibility score: stress score−rest score>1), andto have a fixed defect if the assigned regional grade at stress wasabnormal and remained the same on rest imaging. The fixed defects weresubgrouped on the basis of the severity of the graded scores, ie,mild-to-moderate (scores of 1, 2, and 3) and severe (score of 4). Theglobal extent of perfusion abnormality and ischemia was assessed bysumming the individual scores from the 20 segments, and expressed as theaverage stress and average reversibility scores, respectively.

Safety was monitored by evaluating AEs, laboratory data, and the resultsof physical examinations. A Data and Safety Monitoring Board (DSMB)reviewed SAEs and results of laboratory tests approximately every 6weeks. Acute cardiac events were adjudicated by a Clinical EventsCommittee (CEC). Core laboratories reviewed the results of angiograms,ECGs, ophthalmologic evaluations, and nuclear scans.

Demographic and Other Subject Characteristics

Table 8 summarizes demographic features of the subjects enrolled in thetrial. These features were similar among the four treatment groups(Table 8).

TABLE 8 Summary of Demography Treatment Group Placebo 0.3 μg/kg 3.0μg/kg 30 μg/kg Age (mean years)  63.9  63.0  62.9  61.8 Percent male sex 86%  84%  80%  86% Percent Caucasian race  97%  90%  94%  93% Weight(mean kg)  88.24  87.25  87.23  87.50 Height (mean cm) 170.94 172.02172.45 171.99 Percent tobacco use  8%  11%  10%  10%Primary Efficacy AnalysisAnalysisExercise Tolerance Testing

FIG. 9 shows the ETT time at baseline, at Day 90, and the primaryefficacy variable, change in ETT time from baseline to Day 90. In thisand the tabulations of all efficacy variables, subjects who hadundergone a revascularization and subjects with no assessment wereexcluded from the analysis unless otherwise specified. The mean increasein exercise time was 44.1 seconds for the placebo group, 48.5 seconds inthe low-dose group, 65.0 seconds in the middle-dose group, and 49.1seconds in the high-dose group.

FIG. 9 also shows ETT time at Day 180 and the change in ETT time frombaseline to Day 180. The mean increase in exercise time was 54.8 secondsin the placebo group, 75.3 seconds in the low-dose group, 76.3 secondsin the middle-dose group, and 51.3 seconds in the high-dose group.Trends in improvement in ETT were observed at Day 180 in subjects with abaseline CCS of 3 or 4 and/or SAQ angina frequency of less than or equalto 40.

Seattle Angina Questionnaire

FIG. 10 shows the analyses of the SAQ. A change of ≧8 points isconsidered clinically meaningful and higher SAQ scores are associatedwith better clinical status. For AFS change scores at Day 90, the Pvalues were 0.035 based upon the overall test and 0.007 based upon thetest of placebo versus all FGF. The mean change from baseline was 8.1for the placebo group, 16.0 for the low-dose group, 20.8 for themiddle-dose group, and 16.7 for the high-dose group (pairwise Pvalues=0.080, 0.004, 0.054, respectively). For AFS change scores at Day180, the mean change was 15.3 for the placebo group, 18.7 for thelow-dose group, 22.6 for the middle-dose group, and 20.2 for thehigh-dose group (pairwise P values=0.44, 0.089, 0.25, respectively). Theremaining SAQ scales, Exertional Capacity, Treatment Satisfaction, andDisease Perception, are shown for the FGF treatment groups in FIG. 11.

Short Form 36

FIG. 12 shows the analysis for the SF-36 Physical Component SummaryScale (PCSS) and Mental Component Summary Scale (MCSS). For the PCSS atDay 90, the P value based on the test of placebo versus all FGF was0.033. The mean change from baseline was 3.4 in the placebo group, 6.0in the low-dose group, 5.9 in the middle-dose group, and 5.9 in thehigh-dose group (pairwise P values=0.072, 0.091, 0.095, respectively).For PCSS at Day 180, the difference in the mean change from baseline wasless than 2.2 between the placebo and FGF groups. Treatment effect wasnot detectable in the MCSS (mental component) of the SF-36.

Nuclear Imaging

Consistent differences among the placebo and FGF groups were notdetectable.

Examination of Subgroups

Exercise Tolerance Testing

FIG. 13 (left panel) show ETT time for subjects with baseline CCS of 3or 4. The mean change in exercise time from baseline to Day 90 forsubjects with a baseline CCS of 3 or 4 was 36.1 seconds for the placebogroup, 47.6 seconds for the low-dose group, 57.1 seconds for themiddle-dose group, and 44.5 seconds in the high-dose group (pairwise Pvalues=0.59, 0.31, 0.69, respectively). The mean change in exercise timefrom baseline to Day 180 was 33.1 seconds for the placebo group, 70.7seconds for the low-dose group, 75.7 seconds for the middle-dose group,and 41.5 seconds for the high-dose group (pairwise P values=0.15, 0.086,0.74, respectively).

FIG. 13 (right panel) shows SAQ scores for subjects with baseline CCS of3 or 4. The mean change in AFS from baseline to Day 90 for subjects witha baseline CCS of 3 or 4 was 5.7 for the placebo group, 17.0 for thelow-dose group, 19.5 for the middle-dose group, and 20.5 for thehigh-dose group (pairwise P values=0.058, 0.015, 0.010, respectively).At Day 180, the mean change in AFS was 11.7 for the placebo group, 17.2for the low-dose group, 22.3 for the middle-dose group, and 21.8 for thehigh-dose group (pairwise P values=0.34, 0.059, 0.076, respectively).

FIG. 14 (left panel) shows ETT time for subjects with baseline AnginaFrequency Score (AFS) of ≦40, as measured using the Seattle AnginaQuestionnaire (SAQ). The mean change in exercise time from baseline toDay 90 for subjects with a baseline AFS≦40 (lower scores indicating ahigher frequency of angina) was 50.3 seconds for the placebo group, 83.6seconds for the low-dose group, 72.1 seconds for the middle-dose group,and 49.8 seconds for the high-dose group (pairwise P values=0.16, 0.32,0.98, respectively). The mean change in exercise time from baseline toDay 180 was 56.5 seconds for the placebo group, 90.2 seconds for thelow-dose group, 84.6 seconds for the middle-dose group, and 55.0 secondsfor the high-dose group (pairwise P values=0.24, 0.29, 0.96,respectively).

These data suggest a higher mean change in ETT time for subjects with ahigher frequency of angina at baseline and who received the low ormiddle doses of FGF compared to those who received placebo.

FIG. 14 (right panel) shows AFS for subjects with baseline AFS of ≦40.The mean change in AFS from baseline to Day 90 for subjects with abaseline AFS≦40 (lower scores indicating a higher frequency of angina)was 12.2 for the placebo group, 27.7 for the low-dose group, 29.7 forthe middle-dose group, and 22.0 for the high-dose group (pairwise Pvalues=0.017, 0.004, 0.10, respectively). At Day 180, the mean change inAFS was 16.3 for the placebo group, 27.4 for the low-dose group, 30.7for the middle-dose group, and 24.6 for the high-dose group (pairwise Pvalues=0.089, 0.019, 0.18, respectively). The magnitude of thedifference in AFS between the low and middle dose groups and placebo insubjects with lower AFS at baseline was considered clinically relevant.

Functional Analysis

Anatomy

At 90 days there was a significant reduction in Left Ventricular EndDiastolic Diameter (LVEDD) in the 3.0 μg/kg dosage group and in the 30μg/kg dosage group (p=0.037 and 0.032, respectively). There was a trendto improvement in the 0.3 μg/kg dosage group (p=0.13). In controls,LVEDD slightly increased. This is consistent with relief of ischemia andan improvement in function in FGF treated patients (3.0 μg/kg and 30μg/k dose groups). At 90 days there is a significant reduction in LeftVentricular End Systolic Diameter (LVESD) in the 0.3 μg/kg dose group(p=0.042) and the 30 μg/kg dose group (p=0.024) and a trend (p=0.17) inthe 3.0 μg/kg group. This is also consistent with a relief of ischemiaand an improvement in function in FGF-treated patients. Controls showedan increase in LVESD (consistent with an increase in LVEDD). The effectis not evident at 6 months. Left Ventricular (LV) mass was unchanged, aswould be expected (because there was no effect on blood pressure, noeffect on LV mass was expected).

Wall Motion

Normal wall motion is in the expected range (30–40%) and was unchanged.Normal wall thickening is in the expected range (45–50%) and isunchanged. Target wall, i.e., the wall of the myocardium that isischemic, motion at rest was the same as normal.

Myocardial Perfusion

Delayed arrival zone (DAZ) was similar across all groups at baseline(mean˜15%). That correlated with the size of exercise-induced nuclearperfusion defect (˜18%). The size of DAZ declined in all groups. Thehighest decline was in the 3.0 μg/kg group.

Summary and Conclusions

The data from the phase II trial showed an overall pattern that suggeststhat subjects improve most with the low (0.3 μg/kg) and mid-doses (3.0μg/kg) of FGF-2.

Overall, more symptomatic patients showed the most improvement. Forexample, subjects with a baseline of CCS of 3 or 4 and/or SAQ AnginaFrequency of ≦40showed a trend toward improvement at ETT at Day 180.

For all subject groups, reduction of angina frequency (p=0.035) wasobserved at Day 90. The subjects with a baseline of CCS of 3 or 4 and/orSAQ Angina Frequency of ≦40 showed the most improvement at both Day 90and Day 180. Further, subjects with a baseline of CCS or 3 or 4 showedimprovement in the SF-36 Physical Component at both Day 90 and Day 180.

Further, MRI data provided evidence of improved LV function in FGFgroups as evidenced by reduced LVEDD and LVESD. Perfusion analysisshowed a trend toward improvement in FGF groups.

For the secondary efficacy variables of the SAQ, changes ≧8 areconsidered clinically relevant; a statistically significant differencewas seen in the overall analysis of the angina frequency score (AFS).Differences that were clinically relevant and statistically significantwere seen between the placebo and the middle-dose groups in AFS at Day90.

For the secondary efficacy variables of the SF-36, a significantdifference between the placebo and all FGF-treated groups was seen inthe physical component summary scale (PCSS) at Day 90 (0.033).

Additionally, in a subset of patients with congestive heart failure,improvement was seen with any dose of FGF. Thus, FGF may be more helpfulin patients with congestive heart failure. In the phase II study, at day90, patients receiving placebo showed a change of 23.2 seconds (leastsquare mean) from baseline for total exercise time as compared withpatients receiving low doses and mid-range doses who showed a change of64.6 and 81.3, respectively. At day 180, the placebo showed a change intotal exercise time of 27.3 seconds as compared to 75.4 seconds and 72.8seconds for the low dose and mid-dose groups. The results establish astatistical trend in mid and low dosage groups at day 90.

1. A method for treating a human patient for congestive heart failure,comprising administering a single unit dose of a therapeuticallyeffective amount of a recombinant FGF-2 or an angiogenically activefragment or an angiogenically active mutein thereof into one or morecoronary vessels or into a peripheral vein in a human patient in need oftreatment for said congestive heart failure, said therapeuticallyeffective amount being about 0.2 μg/kg to 48 μg/kg of patient weight,wherein said mutein has at least 85% sequence identity to the FGF-2 ofSEQ ID NO: 2 and retains at least 50% of the angiogenic activity of theFGF-2 of SEQ ID NO:
 2. 2. The method of claim 1, wherein said unit doseis administered by infusion.
 3. The method of claim 1, wherein saidrecombinant FGF-2 has the amino acid sequence of SEQ ID NO:
 2. 4. Themethod of claim 3, further comprising the step of administering to saidhuman patient about 10 U/kg to 80 U/kg of heparin within 30 minutes ofadministering said unit dose, wherein said heparin is administered byintravenous or intracoronary administration.
 5. The method of claim 4,wherein said unit dose is administered into one or more coronaryvessels.
 6. The method of claim 5, wherein said therapeuticallyeffective amount of said recombinant FGF-2 of SEQ ID NO: 2 or saidangiogenically active fragment or said angiogenically active muteinthereof is about 24 μg/kg to 48 μg/kg.
 7. The method of claim 4, whereinsaid unit dose is administered into a peripheral vein.
 8. The method ofclaim 7, wherein said therapeutically effective amount of saidrecombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragmentor said angiogenically active mutein thereof is about 18 μg/kg to 36μg/kg.
 9. A method for treating a human patient for congestive heartfailure, comprising administering a single unit dose of a recombinantFGF-2 or an angiogenically active fragment or an angiogenically activemutein thereof into one or more coronary vessels or into a peripheralvein in a human patient in need of treatment for congestive heartfailure, said unit dose comprising from about 0.008 mg to 7.2 mg of saidrecombinant FGF-2 or said angiogenically active fragment or saidangiogenically active mutein thereof, wherein said mutein has at least85% sequence isdentity to the FGF-2 of SEQ ID NO: 2 and retains at least50% of the angiogenic activity of the FGF-2 of SEQ ID NO:
 2. 10. Themethod of claim 9, wherein said unit dose is administered by infusion.11. The method of claim 9, wherein said FGF-2 has the amino acidsequence of SEQ ID NO:
 2. 12. The method of claim 11, wherein said unitdose comprises 0.3 mg to 3.5 mg of said recombinant FGF-2 of SEQ ID NO:2 or said angiogenically active fragment or said angiogenically activemutein thereof.
 13. The method of claim 11, further comprising the stepof administering 10 U/kg to 80 U/kg of heparin to said patient withinabout 30 minutes of administering said unit dose, wherein said heparinis administered by intravenous or intracoronary administration.
 14. Themethod of claim 13, wherein said unit dose is administered into one ormore coronary vessels.
 15. The method of claim 13, wherein said unitdose is administered into a peripheral vein.
 16. The method of claim 11,wherein said single unit dose produces a therapeutic benefit againstcongestive heart failure in said human patient that lasts at least 4months.
 17. The method of claim 16, wherein said therapeutic benefit insaid human patient lasts 6 months.
 18. The method of claim 17, whereinsaid single unit dose produces a therapeutic benefit of such magnitudeand duration in said human patient such that administration of a secondunit dose is not required for about 6 /months.